Ten O
compounds O
have O
been O
identified O
, O
in O
which O
3 B
- I
methylthio I
- I
1 I
- I
propene I
was O
the O
most O
significant O
component O
. O

The O
main O
components O
in O
the O
oil O
were O
beta B
- I
caryophyllene I
( O
56 O
. O
87 O
% O
) O
, O
alpha B
- I
cadinol I
( O
12 O
. O
52 O
% O
) O
, O
8S B
, I
13 I
- I
cedran I
- I
diol I
( O
5 O
. O
41 O
% O
) O
, O
alpha B
- I
terpineol I
( O
3 O
. O
99 O
% O
) O
, O
beta B
- I
eudesmol I
( O
2 O
. O
54 O
% O
) O
, O
caryophyllene B
oxide I
( O
2 O
. O
51 O
% O
) O
and O
ethyl B
iso I
- I
allocholate I
( O
2 O
. O
03 O
% O
) O
along O
with O
beta B
- I
cubebene I
, O
gamma B
- I
cadinene I
, O
cubenol B
, O
1 B
, I
8 I
- I

cineol I
, O
o B
- I
cymene I
, O
curcumenol B
, O
spathulenol B
, O
friedeline B
and O
beta B
- I
sitosterol I
as O
minor O
constituents O
. O

CNS O
distribution O
of O
metabotropic O
glutamate B
2 O
and O
3 O
receptors O
: O
transgenic O
mice O
and O
[ B
( I
3 I
) I
H I
] I
LY459477 I
autoradiography O
. O

There O
was O
virtually O
no O
binding O
of O
[ B
( I
3 I
) I
H I
] I
LY459477 I
to O
any O
brain O
region O
in O
mice O
with O
a O
deletion O
of O
both O
mGlu O
( O
2 O
) O
and O
mGlu O
( O
3 O
) O
receptors O
. O

These O
findings O
suggest O
[ B
( I
3 I
) I
H I
] I
LY459477 I
should O
be O
a O
useful O
tool O
to O
further O
define O
the O
role O
of O
mGlu O
( O
2 O
) O
and O
mGlu O
( O
3 O
) O
receptors O
throughout O
the O
brain O
with O
respect O
to O
major O
neuropsychiatric O
syndromes O
. O

In O
particular O
, O
we O
have O
isolated O
and O
identified O
harpagide B
, O
7 B
- I
beta I
- I
hydroxy I
- I
harpagide I
, O
ajugol B
, O
5 B
- I
allosyloxy I
- I
aucubin I
, O
verbascoside B
and O
, O
for O
the O
first O
time O
in O
this O
genus O
, O
arbutin B
. O

A O
new O
xanthone B
, O
calothorexanthone B
, O
together O
with O
five O
known O
compounds O
, O
garbogiol B
, O
1 B
, I
4 I
, I
8 I
- I
trihydroxyxanthone I
, O
delta B
- I
tocotrienol I
, O
1 B
, I
7 I
- I
dihydroxyxanthone I
and O
globuxanthone B
, O
was O
isolated O
from O
a O
petroleum O
ether O
extract O
of O
the O
bark O
of O
Calophyllum O
thorelii O
. O

Mouse O
hippocampal O
synaptosomes O
were O
preloaded O
with O
[ B
( I
3 I
) I
H I
] I
D I
- I
gamma I
- I
aminobutyric I
acid I
( O
[ B
( I
3 I
) I
H I
] I
GABA I
) O
and O
then O
exposed O
in O
superfusion O
to O
12 O
mM O
KCl B
. O

The O
K B
( I
+ I
) I
- O
evoked O
[ B
( I
3 I
) I
H I
] I
GABA I
release O
was O
inhibited O
by O
the O
mGlu7 O
allosteric O
agonist O
N B
, I
N I
' I
- I
dibenzyhydryl I
- I
ethane I
- I
1 I
, I
2 I
- I
diamine I
dihydrochloride I
( O
AMN082 B
, O
0 O
. O
001 O
- O
10 O
mu O
M O
) O
, O
as O
well O
as O
by O
the O
group O
III O
mGlu O
receptor O
agonist O
l B
- I
( I
+ I
) I
- I
2 I
- I
amino I
- I
4 I
- I
phosphonobutyric I
acid I
[ O
( B
l I
) I
- I
AP4 I
, O
0 O
. O
01 O
- O
1 O
mM O
] O
. O

AMN082 B
and O
the O
adenylyl O
cyclase O
( O
AC O
) O
inhibitor O
MDL B
- I
12 I
, I
330A I
reduced O
[ B
( I
3 I
) I
H I
] I
GABA I
exocytosis O
in O
a O
8 B
- I
Br I
- I
cAMP I
- O
sensitive O
. O

Finally O
, O
the O
forskolin B
- O
evoked O
[ B
( I
3 I
) I
H I
] I
GABA I
release O
was O
reduced O
by O
AMN082 B
or O
( B
- I
) I
baclofen I
but O
abolished O
when O
the O
two O
agonists O
were O
added O
concomitantly O
. O

The O
stable O
inclusion O
complex O
of O
puerarin B
and O
2 B
- I
hydroxypropyl I
- I
beta I
- I
cyclodextrin I
( O
HPCD B
) O
was O
prepared O
by O
a O
ball O
mill O
under O
the O
following O
conditions O
: O
equimolar O
ratio O
of O
puerarin O
to O
HPCD B
; O
rotational O
speed O
of O
250 O
rpm O
; O
milling O
time O
of O
90 O
min O
; O
steel O
balls O
of O
22 O
mm O
diameter O
. O

Selective O
I O
( O
2 O
) O
- O
imidazoline B
receptor O
ligands O
induce O
neuroprotection O
through O
various O
molecular O
mechanisms O
including O
blockade O
of O
N B
- I
methyl I
- I
D I
- I
aspartate I
( O
NMDA B
) O
receptors O
. O

To O
investigate O
new O
neuroprotective O
mechanisms O
associated O
with O
I O
( O
2 O
) O
- O
imidazoline B
receptors O
, O
the O
effects O
of O
selective O
( O
2 B
- I
styryl I
- I
2 I
- I
imidazoline I
( O
LSL B
61122 I
) O
, O
2 B
- I
( I
2 I
- I
benzofuranyl I
) I
- I
2 I
- I
imidazoline I
( O
2 B
- I
BFI I
) O
, O
2 B
- I
( I
4 I
, I
5 I
- I
dihydroimidazol I
- I
2 I
- I
yl I
) I
quinoline I
hydrochloride I
( O
BU B
- I
224 I
) O
) O
and O
non O
- O
selective O
( O
idazoxan B
) O
I O
( O
2 O
) O
- O
drugs O
on O

Rescue O
of O
this O
impaired O
extinction O
consolidation O
/ O
retrieval O
was O
achieved O
with O
d B
- I
cycloserine I
( O
N B
- I
methly I
- I
d I
- I
aspartate I
partial O
agonist O
) O
or O
MS B
- I
275 I
( O
histone O
deacetylase O
( O
HDAC O
) O
inhibitor O
) O
, O
applied O
after O
extinction O
training O
. O

Monoisononyl B
phthalate I
( O
MiNP B
) O
, O
mono B
( I
carboxy I
- I
isooctyl I
) I
phthalate I
( O
MCiOP B
) O
, O
mono B
( I
hydroxyl I
- I
isononyl I
) I
phthalate I
( O
MHiNP B
) O
, O
mono B
( I
oxo I
- I
isononyl I
) I
phthalate I
( O
MOiNP B
) O
, O
and O
monoisononyl B
phthalate I
glucuronide I
( O
MiNP B
- I
G I
) O
were O
found O
in O
all O
measured O
tissues O
. O

Monoisononyl B
phthalate I
( O
MiNP B
) O
, O
mono B
( I
carboxy I
- I
isooctyl I
) I
phthalate I
( O
MCiOP B
) O
, O
mono B
( I
hydroxyl I
- I
isononyl I
) I
phthalate I
( O
MHiNP B
) O
, O
mono B
( I
oxo I
- I
isononyl I
) I
phthalate I
( O
MOiNP B
) O
, O
and O
monoisononyl B
phthalate I
glucuronide I
( O
MiNP B
- I
G I
) O
were O
found O
in O
all O
measured O
tissues O
. O

Monoisononyl B
phthalate I
( O
MiNP B
) O
, O
mono B
( I
carboxy I
- I
isooctyl I
) I
phthalate I
( O
MCiOP B
) O
, O
mono B
( I
hydroxyl I
- I
isononyl I
) I
phthalate I
( O
MHiNP B
) O
, O
mono B
( I
oxo I
- I
isononyl I
) I
phthalate I
( O
MOiNP B
) O
, O
and O
monoisononyl B
phthalate I
glucuronide I
( O
MiNP B
- I
G I
) O
were O
found O
in O
all O
measured O
tissues O
. O

Cellular O
reactive O
oxygen B
species O
production O
induced O
by O
tBHP B
was O
attenuated O
by O
pretreatment O
with O
chrysin B
, O
apigenin B
, O
and O
luteolin B
( O
P O
< O
. O
05 O
) O
, O
and O
this O
protection O
was O
reversed O
by O
the O
GCL O
inhibitor O
l B
- I
buthionine I
- I
S I
- I
sulfoximine I
and O
the O
HO O
- O
1 O
inhibitor O
zinc B
protoporphyrin I
. O

Our O
results O
indicate O
that O
the O
compound O
[ B
3 I
- I
13 I
] I
- I
alloferon I
( O
1 O
) O
exhibits O
the O
strongest O
antiviral O
activity O
( O
IC O
( O
50 O
) O
= O
38 O
mu O
M O
) O
among O
the O
analyzed O
compound O
. O

Di B
- I
2 I
- I
ethyl I
hexyl I
phthalate I
( O
DEHP B
) O
, O
an O
industrial O
plasticizer O
and O
a O
ubiquitous O
environmental O
contaminant O
, O
is O
an O
established O
endocrine O
disruptor O
( O
ED O
) O
. O

Extracellular O
Ca B
( I
2 I
+ I
) I
removal O
, O
amiloride B
, O
and O
the O
antioxidant O
N B
- I
acetyl I
- I
l I
- I
cysteine I
significantly O
blunted O
withaferin B
A I
- O
triggered O
annexin O
- O
V O
- O
binding O
. O

Volatile O
compounds O
identified O
by O
GC O
- O
MS O
analysis O
showed O
that O
the O
content O
of O
the O
important O
meaty O
flavour O
compounds O
( O
such O
as O
2 B
- I
methyl I
- I
3 I
- I
furanthiol I
, O
bis B
( I
2 I
- I
methyl I
- I
3 I
- I
furyl I
) I
disulfide I
) O
of O
MSPC O
were O
dramatically O
higher O
than O
that O
of O
MRPs O
from O
uncross O
- O
linking O
peptides O
. O

1 O
. O
Metabolic O
disposition O
of O
( B
14 I
) I
C I
- I
abiraterone I
acetate I
( O
AA O
) O
, O
a O
prodrug O
of O
abiraterone B
was O
assessed O
in O
a O
phase O
I O
, O
open O
- O
label O
, O
single O
- O
dose O
( O
1000 O
mg O
, O
approximately O
100 O
mu O
Ci O
) O
study O
in O
healthy O
males O
( O
18 O
- O
55 O
years O
, O
N O
= O
8 O
) O
. O

The O
present O
study O
investigated O
the O
protective O
effect O
of O
CYT B
on O
cultured O
cortical O
neural O
injury O
induced O
by O
N B
- I
methyl I
- I
d I
- I
aspartate I
( O
NMDA B
) O
. O

In O
a O
human O
radiolabel O
study O
, O
six O
healthy O
men O
received O
a O
single O
oral O
dose O
of O
200 O
mu O
g O
of O
[ B
( I
14 I
) I
C I
] I
vilanterol I
( O
74 O
kBq O
) O
. O

In O
vivo O
, O
an O
extensive O
metabolism O
of O
[ B
( I
18 I
) I
F I
] I
DPA I
- I
714 I
was O
observed O
in O
rats O
and O
baboons O
, O
identified O
as O
[ B
( I
18 I
) I
F I
] I
deethyl I
, O
[ B
( I
18 I
) I
F I
] I
hydroxyl I
, O
and O
[ B
( I
18 I
) I
F I
] I
carboxylic I
acid I
derivatives O
of O
[ B
( I
18 I
) I
F I
] I
DPA I
- I
714 I
. O

In O
vivo O
, O
an O
extensive O
metabolism O
of O
[ B
( I
18 I
) I
F I
] I
DPA I
- I
714 I
was O
observed O
in O
rats O
and O
baboons O
, O
identified O
as O
[ B
( I
18 I
) I
F I
] I
deethyl I
, O
[ B
( I
18 I
) I
F I
] I
hydroxyl I
, O
and O
[ B
( I
18 I
) I
F I
] I
carboxylic I
acid I
derivatives O
of O
[ B
( I
18 I
) I
F I
] I
DPA I
- I
714 I
. O

Mixed O
cultures O
of O
mouse O
cortical O
cells O
were O
challenged O
with O
toxic O
concentrations O
of O
N B
- I
methyl I
- I
d I
- I
aspartate I
( O
NMDA B
) O
for O
10 O
min O
, O
and O
neuronal O
death O
was O
assessed O
20 O
h O
later O
. O

Improved O
preparation O
of O
methyl B
bis I
( I
2 I
, I
2 I
, I
2 I
- I
trifluoroethoxy I
) I
- I
bromophosphonoacetat I
for O
the O
stereoselective O
synthesis O
of O
( B
E I
) I
- I
alpha I
- I
bromoacrylates I
. O

We O
have O
established O
an O
efficient O
method O
for O
preparing O
methyl B
bis I
( I
2 I
, I
2 I
, I
2 I
- I
trifluoroethoxy I
) I
bromophosphonoacetat I
, O
which O
we O
developed O
for O
the O
stereoselective O
synthesis O
of O
( B
E I
) I
- I
alpha I
- I
bromoacrylates I
. O

The O
effects O
of O
ultrasound O
irradiation O
, O
concentration O
, O
pH O
and O
sequential O
dipping O
steps O
on O
growth O
of O
the O
Mg B
( I
OH I
) I
( I
2 I
) I
nanostructures O
have O
been O
studied O
. O

LPV B
( O
5 O
micro O
M O
) O
, O
alone O
and O
combined O
with O
5 O
micro O
M O
RTV B
, O
significantly O
decreased O
[ B
( I
3 I
) I
H I
] I
TCA I
accumulation O
in O
cells O
+ O
bile O
of O
SCRHs O
compared O
with O
control O
. O

LPV B
/ O
r O
significantly O
increased O
[ B
( I
3 I
) I
H I
] I
TCA I
cellular O
accumulation O
( O
7 O
. O
7 O
+ O
/ O
- O
0 O
. O
1 O
pmol O
/ O
mg O
of O
protein O
) O
compared O
with O
vehicle O
and O
5 O
micro O
M O
LPV B
alone O
( O
5 O
. O
1 O
+ O
/ O
- O
0 O
. O
7 O
and O
5 O
. O
0 O
+ O
/ O
- O
0 O
. O
5 O
pmol O
/ O
mg O
of O
protein O
) O
. O

The O
[ B
( I
3 I
) I
H I
] I
TCA I
biliary O
clearance O
was O
reduced O
significantly O
by O
LPV B
and O
RTV B
and O
further O
reduced O
by O
LPV B
/ O
r O
. O

LPV B
and O
RTV B
did O
not O
affect O
the O
initial O
uptake O
rates O
of O
[ B
( I
3 I
) I
H I
] I
TCA I
or O
[ B
( I
14 I
) I
C I
] I
CDCA I
in O
suspended O
rat O
hepatocytes O
. O

LPV B
and O
RTV B
did O
not O
affect O
the O
initial O
uptake O
rates O
of O
[ B
( I
3 I
) I
H I
] I
TCA I
or O
[ B
( I
14 I
) I
C I
] I
CDCA I
in O
suspended O
rat O
hepatocytes O
. O

The O
majority O
of O
protein O
sulfhydryl B
depletion O
was O
due O
to O
reversible O
oxidation O
since O
the O
global O
- O
and O
lobule O
- O
specific O
effects O
were O
essentially O
reversed O
when O
the O
samples O
were O
reduced O
with O
tris B
( I
2 I
- I
carboxyethy I
) I
phosphine I
before O
maleimide B
labeling O
. O

The O
potency O
at O
P2Y O
( O
12 O
) O
was O
2 B
- I
( I
methylthio I
) I
- I
ADP I
> O
2 B
- I
( I
methylthio I
) I
- I
ATP I
> O
ADP B
> O
ATP B
. O

The O
potency O
at O
P2Y O
( O
12 O
) O
was O
2 B
- I
( I
methylthio I
) I
- I
ADP I
> O
2 B
- I
( I
methylthio I
) I
- I
ATP I
> O
ADP B
> O
ATP B
. O

The O
insulin O
- O
like O
and O
/ O
or O
insulin O
- O
sensitising O
effects O
of O
Syzygium O
aqueum O
leaf O
extract O
and O
its O
six O
bioactive O
compounds O
; O
4 B
- I
hydroxybenzaldehyde I
, O
myricetin B
- I
3 I
- I
O I
- I
rhamnoside I
, O
europetin B
- I
3 I
- I
O I
- I
rhamnoside I
, O
phloretin B
, O
myrigalone B
- I
G I
and O
myrigalone B
- I
B I
were O
investigated O
in O
3T3 O
- O
L1 O
adipocytes O
. O

The O
insulin O
- O
like O
and O
/ O
or O
insulin O
- O
sensitising O
effects O
of O
Syzygium O
aqueum O
leaf O
extract O
and O
its O
six O
bioactive O
compounds O
; O
4 B
- I
hydroxybenzaldehyde I
, O
myricetin B
- I
3 I
- I
O I
- I
rhamnoside I
, O
europetin B
- I
3 I
- I
O I
- I
rhamnoside I
, O
phloretin B
, O
myrigalone B
- I
G I
and O
myrigalone B
- I
B I
were O
investigated O
in O
3T3 O
- O
L1 O
adipocytes O
. O

Clearly O
, O
the O
compounds O
myricetin B
- I
3 I
- I
O I
- I
rhamnoside I
and O
europetin B
- I
3 I
- I
O I
- I
rhamnoside I
showed O
insulin O
- O
like O
and O
insulin O
- O
sensitising O
effects O
on O
adipocytes O
from O
a O
concentration O
of O
0 O
. O
08 O
mu O
M O
. O

Clearly O
, O
the O
compounds O
myricetin B
- I
3 I
- I
O I
- I
rhamnoside I
and O
europetin B
- I
3 I
- I
O I
- I
rhamnoside I
showed O
insulin O
- O
like O
and O
insulin O
- O
sensitising O
effects O
on O
adipocytes O
from O
a O
concentration O
of O
0 O
. O
08 O
mu O
M O
. O

Foliage O
of O
Coriandrum O
sativum O
is O
a O
rich O
source O
of O
natural O
folates O
amenable O
for O
enhancement O
through O
salicylic B
acid I
- O
mediated O
elicitation O
, O
thereby O
holding O
a O
great O
promise O
for O
natural O
- O
mode O
alleviation O
of O
this O
vitamin B
( I
B I
( I
9 I
) I
) I
deficiency O
. O

2 B
- I
Amino I
- I
4 I
- I
arylthiazole I
compounds O
as O
TRPA1 O
antagonists O
( O
WO O
2012085662 O
) O
: O
a O
patent O
evaluation O
. O

The O
patent O
claims O
2 B
- I
amino I
- I
4 I
- I
arylthiazole I
derivative O
compounds O
as O
inhibitors O
of O
the O
TRPA1 O
( O
transient O
receptor O
potential O
ankyrin O
, O
member O
1 O
) O
receptor O
. O

The O
2 B
, I
2 I
' I
, I
4 I
, I
4 I
' I
- I
tetrabromodiphenyl I
ether I
hydroxylated O
metabolites O
5 B
- I
OH I
- I
BDE I
- I
47 I
and O
6 B
- I
OH I
- I
BDE I
- I
47 I
stimulate O
estradiol B
secretion O
in O
the O
ovary O
by O
activating O
aromatase O
expression O
. O

The O
2 B
, I
2 I
' I
, I
4 I
, I
4 I
' I
- I
tetrabromodiphenyl I
ether I
hydroxylated O
metabolites O
5 B
- I
OH I
- I
BDE I
- I
47 I
and O
6 B
- I
OH I
- I
BDE I
- I
47 I
stimulate O
estradiol B
secretion O
in O
the O
ovary O
by O
activating O
aromatase O
expression O
. O

The O
aim O
of O
the O
present O
study O
was O
to O
assess O
the O
effect O
of O
two O
hydroxylated B
BDE I
- I
47 I
metabolites O
, O
5 B
- I
OH I
- I
BDE I
- I
47 I
and O
6 B
- I
OH I
- I
BDE I
- I
47 I
, O
on O
steroidogenesis O
in O
the O
ovary O
. O

The O
aim O
of O
the O
present O
study O
was O
to O
assess O
the O
effect O
of O
two O
hydroxylated B
BDE I
- I
47 I
metabolites O
, O
5 B
- I
OH I
- I
BDE I
- I
47 I
and O
6 B
- I
OH I
- I
BDE I
- I
47 I
, O
on O
steroidogenesis O
in O
the O
ovary O
. O

Direct O
assessment O
of O
aromatase O
activity O
by O
dibenzylfluorescein B
assay O
and O
indirect O
assessment O
of O
aromatase O
activity O
by O
measurement O
of O
the O
conversion O
of O
testosterone B
to O
estradiol B
confirmed O
that O
5 B
- I
OH I
- I
BDE I
- I
47 I
and O
6 B
- I
OH I
- I
BDE I
- I
47 I
stimulate O
aromatase O
activity O
. O

Direct O
assessment O
of O
aromatase O
activity O
by O
dibenzylfluorescein B
assay O
and O
indirect O
assessment O
of O
aromatase O
activity O
by O
measurement O
of O
the O
conversion O
of O
testosterone B
to O
estradiol B
confirmed O
that O
5 B
- I
OH I
- I
BDE I
- I
47 I
and O
6 B
- I
OH I
- I
BDE I
- I
47 I
stimulate O
aromatase O
activity O
. O

The O
aldehyde B
dehydrogenase O
( O
ALDH O
) O
superfamily O
is O
composed O
of O
nicotinamide B
adenine I
dinucleotide I
( I
phosphate I
) I
( O
NAD B
( I
P I
) I
( I
+ I
) I
) O
- O
dependent O
enzymes O
that O
catalyze O
the O
oxidation O
of O
aldehydes B
to O
their O
corresponding O
carboxylic B
acids I
. O

2 O
. O
[ B
( I
14 I
) I
C I
] I
Darexaban I
was O
rapidly O
absorbed O
, O
with O
both O
blood O
and O
plasma O
concentrations O
peaking O
at O
approximately O
0 O
. O
75 O
h O
post O
- O
dose O
. O

Neurodegeneration O
was O
related O
with O
decreased O
[ B
( I
3 I
) I
H I
] I
glutamate I
uptake O
and O
decreased O
Akt O
immunoreactivity O
, O
however O
phospho O
- O
GSK O
- O
3 O
- O
beta O
( O
Ser9 B
) O
was O
not O
altered O
in O
( B
PhTe I
) I
( I
2 I
) I
injected O
rat O
. O

1 O
. O
When O
benzophenone B
- I
3 I
( O
2 B
- I
hydroxy I
- I
4 I
- I
methoxybenzophenone I
; O
BP B
- I
3 I
) O
was O
incubated O
with O
liver O
microsomes O
of O
untreated O
rats O
in O
the O
presence O
of O
NADPH B
, O
the O
5 O
- O
hydroxylated O
metabolite O
, O
2 B
, I
5 I
- I
dihydroxy I
- I
4 I
- I
methoxybenzophenone I
( O
5 B
- I
OH I
- I
BP I
- I
3 I
) O
, O
was O
formed O
as O
a O
major O
novel O
metabolite O
of O
BP B
- I
3 I
. O

1 O
. O
When O
benzophenone B
- I
3 I
( O
2 B
- I
hydroxy I
- I
4 I
- I
methoxybenzophenone I
; O
BP B
- I
3 I
) O
was O
incubated O
with O
liver O
microsomes O
of O
untreated O
rats O
in O
the O
presence O
of O
NADPH B
, O
the O
5 O
- O
hydroxylated O
metabolite O
, O
2 B
, I
5 I
- I
dihydroxy I
- I
4 I
- I
methoxybenzophenone I
( O
5 B
- I
OH I
- I
BP I
- I
3 I
) O
, O
was O
formed O
as O
a O
major O
novel O
metabolite O
of O
BP B
- I
3 I
. O

The O
4 O
- O
desmethylated O
metabolite O
, O
2 B
, I
4 I
- I
dihydroxybenzophenon I
( O
2 B
, I
4 I
- I
diOH I
- I
BP I
) O
, O
previously O
reported O
as O
the O
major O
in O
vivo O
metabolite O
of O
BP B
- I
3 I
, O
was O
also O
detected O
. O

However O
, O
the O
amount O
of O
5 B
- I
OH I
- I
BP I
- I
3 I
formed O
in O
vitro O
was O
about O
the O
same O
as O
that O
of O
2 B
, I
4 I
- I
diOH I
- I
BP I
. O

However O
, O
the O
amount O
of O
5 B
- I
OH I
- I
BP I
- I
3 I
formed O
in O
vitro O
was O
about O
the O
same O
as O
that O
of O
2 B
, I
4 I
- I
diOH I
- I
BP I
. O

2 O
. O
The O
oxidase O
activity O
affording O
5 B
- I
OH I
- I
BP I
- I
3 I
was O
inhibited O
by O
SKF B
525 I
- I
A I
and O
ketoconazole B
, O
and O
partly O
by O
quinidine B
and O
sulfaphenazole B
. O

The O
oxidase O
activity O
affording O
2 B
, I
4 I
- I
diOH I
- I
BP I
was O
inhibited O
by O
SKF B
525 I
- I
A I
, O
ketoconazole B
and O
alpha B
- I
naphthoflavone I
, O
and O
partly O
by O
sulfaphenazole B
. O

3 O
. O
The O
oxidase O
activity O
affording O
5 B
- I
OH I
- I
BP I
- I
3 I
was O
enhanced O
in O
liver O
microsomes O
of O
dexamethasone B
- O
, O
phenobarbital B
- O
and O
3 B
- I
methylcholanthrene I
- O
treated O
rats O
. O

The O
activity O
affording O
2 B
, I
4 I
- I
diOH I
- I
BP I
was O
enhanced O
in O
liver O
microsomes O
of O
3 B
- I
methylcholanthrene I
- O
and O
phenobarbital B
- O
treated O
rats O
. O

( B
S I
) I
- I
2 I
- I
phenylglycinol I
and O
Triton B
X I
- I
100 I
proved O
to O
be O
the O
best O
organocatalyst O
and O
surfactant O
, O
respectively O
. O

The O
AA O
% O
of O
the O
tea O
products O
was O
determined O
using O
a O
2 B
, I
2 I
' I
- I
diphenyl I
picrylhydrazyl I
( O
DPPH B
) O
radical O
assay O
method O
. O

Cyanidin B
- I
3 I
- I
O I
- I
glucoside I
was O
the O
anthocyanin B
most O
highly O
correlated O
with O
AA O
% O
( O
r O
= O
0 O
. O
843 O
( O
* O
* O
) O
, O
p O
< O
= O
0 O
. O
01 O
in O
unaerated O
tea O
) O
. O

Initial O
uptake O
rate O
and O
steady O
- O
state O
cell O
- O
to O
- O
medium O
ratio O
of O
[ B
( I
3 I
) I
H I
] I
MTX I
were O
correlated O
with O
both O
RFC1 O
expression O
level O
and O
MTX B
sensitivity O
. O

- I
chloro I
- I
8 I
- I
hydroxy I
- I
3 I
- I
methyl I
- I
1 I
- I
phenyl I
- I
2 I
, I
3 I
, I
4 I
, I
5 I
- I
tetrahydro I
- I
1H I
- I
3 I
- I
benzazepine I
hydrochloride I
( O
SCH23390 B
) O
, O
( B
6aR I
) I
- I
5 I
, I
6 I
, I
6a I
, I
7 I
- I
tetrahydro I
- I
6 I
- I
propyl I
- I
4H I
- I
dibenzo I
[ I
de I
, I
g I
] I
quinoline I
- I
10 I
, I
11 I
- I
diol I
( O
R B
- I
( I
- I
) I
- I
NPA I
) O
, O
haloperidol B
] O
and O

fold O
rightward O
shifts O
in O
the O
ED O
( O
50 O
) O
values O
for O
methamphetamine B
and O
the O
DA O
D O
( O
2 O
) O
agonist O
R B
- I
( I
- I
) I
- I
NPA I
, O
respectively O
. O

Finally O
, O
the O
development O
of O
cross O
- O
tolerance O
to O
methamphetamine B
and O
R B
- I
( I
- I
) I
- I
NPA I
bolsters O
previous O
evidence O
of O
interplay O
between O
CB O
( O
1 O
) O
and O
DA O
D O
( O
2 O
) O
signaling O
mechanisms O
. O

A O
series O
of O
4 B
- I
azaindole I
oxoacetic I
acid I
piperazine I
benzamides I
was O
synthesized O
and O
evaluated O
in O
an O
effort O
to O
identify O
an O
oral O
HIV O
- O
1 O
attachment O
inhibitor O
with O
the O
potential O
to O
improve O
upon O
the O
pre O
- O
clinical O
profile O
of O
BMS B
- I
378806 I
( O
7 O
) O
, O
an O
initial O
clinical O
compound O
. O

Next O
, O
we O
examined O
expression O
of O
genes O
encoding O
five O
progesterone B
metabolizing O
enzymes O
: O
the O
3 B
- I
keto I
and I
20 I
- I
ketosteroid I
reductases O
( O
AKR1C1 O
- O
AKR1C3 O
) O
and O
5 O
alpha O
- O
reductases O
( O
SRD5A1 O
and O
SRD5A2 O
) O
; O
and O
the O
opposing O
20 B
alpha I
- I
hydroxysteroid I
dehydrogenase O
( O
HSD17B2 O
) O
. O

The O
aim O
of O
this O
work O
is O
to O
evaluate O
vitamins B
B I
antimutagenic O
effect O
against O
alkylatings O
methyl B
- I
N I
- I
nitro I
- I
N I
- I
nitrosoguanidine I
( O
MNNG B
) O
, O
ethyl B
- I
N I
- I
nitro I
- I
N I
' I
- I
nitrosoguanidine I
( O
ENNG B
) O
, O
frameshift O
mutagens O
2 B
- I
aminoanthracene I
( O
2AA B
) O
and O
2 B
- I
acetyl I
- I
amino I
- I
fluorene I
( O
2AF B
) O
and O
ROS O
- O
generating O
antibiotics O
norfloxacin B
( O
NOR B
) O
and O
nalidixic B
acid I
( O
NLX B
) O
, O
using O

The O
protein O
amide O
( B
1 I
) I
H I
( I
N I
) I
chemical O
shift O
temperature O
coefficient O
reflects O
thermal O
expansion O
of O
the O
N B
- I
H I
. O
. O
. O
O B
= I
C I
hydrogen B
bond O
. O

The O
protein O
amide O
( B
1 I
) I
H I
( I
N I
) I
chemical O
shift O
temperature O
coefficient O
can O
be O
determined O
with O
high O
accuracy O
by O
recording O
spectra O
at O
different O
temperatures O
, O
but O
the O
physical O
mechanism O
responsible O
for O
this O
temperature O
dependence O
is O
not O
well O
understood O
. O

Parallel O
tempering O
molecular O
dynamics O
simulation O
suggests O
that O
the O
hydrogen B
bond O
distance O
variation O
at O
different O
temperatures O
/ O
replicas O
is O
largely O
responsible O
for O
the O
( B
1 I
) I
H I
( I
N I
) I
chemical O
shift O
temperature O
dependence O
, O
from O
which O
an O
empirical O
equation O
is O
proposed O
to O
predict O
the O
hydrogen B
bond O
thermal O
expansion O
coefficient O
, O
revealing O
responses O
of O
individual O
hydrogen B
bonds O
to O
temperature O
changes O
. O

Antithrombotic O
and O
profibrinolytic O
activities O
of O
isorhamnetin B
- I
3 I
- I
O I
- I
galactoside I
and O
hyperoside B
. O

The O
potential O
anticoagulant O
activities O
of O
two O
single O
compounds O
, O
isorhamnetin B
- I
3 I
- I
O I
- I
galactoside I
( O
IMG B
) O
and O
hyperoside B
, O
from O
Oenanthe O
javanica O
, O
were O
tested O
. O

Synthesis O
of O
polystyrene B
/ O
polysilsesquioxane B
core O
/ O
shell O
composite O
particles O
via O
emulsion O
polymerization O
in O
the O
existence O
of O
poly B
( I
gamma I
- I
methacryloxypropyl I
trimethoxysilane I
) I
sol O
. O

Discovery O
of O
4 B
- I
phenyl I
- I
2 I
- I
phenylaminopyridine I
based O
TNIK O
inhibitors O
. O

A O
series O
of O
compounds O
based O
on O
a O
4 B
- I
phenyl I
- I
2 I
- I
phenylaminopyridine I
scaffold O
that O
are O
potent O
and O
selective O
inhibitors O
of O
Traf2 O
- O
and O
Nck O
- O
interacting O
kinase O
( O
TNIK O
) O
activity O
are O
described O
. O

However O
, O
a O
third O
one O
was O
discovered O
by O
the O
crystal O
structure O
of O
a O
bifunctional O
enzyme O
4 B
- I
hydroxy I
- I
2 I
- I
ketovalerate I
aldolase O
/ O
acylating O
acetaldehyde B
dehydrogenase O
( O
DmpFG O
) O
from O
Pseudomonas O
sp O
. O
strain O
CF600 O
( O
Manjasetty O
et O
al O
. O
, O
Proc O
. O
Natl O
. O
Acad O
. O
Sci O
. O
USA O
100 O
( O
2003 O
) O
6992 O
- O
6997 O
) O
. O

In O
this O
study O
, O
we O
undertook O
the O
characterization O
of O
the O
catalytic O
and O
structural O
properties O
of O
MhpEF O
from O
Escherichia O
coli O
, O
an O
ortholog O
of O
DmpFG O
in O
which O
MhpF O
converts O
acetaldehyde B
, O
produced O
by O
the O
cleavage O
of O
4 B
- I
hydroxy I
- I
2 I
- I
ketovalerate I
by O
MhpE O
, O
into O
acetyl B
- I
CoA I
. O

The O
rotational O
dynamics O
of O
the O
hexafluorophosphate B
anion O
( O
PF B
( I
6 I
) I
( I
- I
) I
) O
in O
the O
crystalline O
and O
liquid O
states O
of O
the O
archetypal O
room O
temperature O
ionic O
liquid O
( O
RTIL O
) O
1 B
- I
butyl I
- I
3 I
- I
methylimidazolium I
hexafluorophosphate I
( O
[ B
C I
( I
4 I
) I
mim I
] I
PF I
( I
6 I
) I
) O
are O
investigated O
using O
( B
31 I
) I
P I
NMR O
spectroscopy O
line O
shape O
analyses O
and O
spin O
- O
lattice O
relaxation O
time O
measurements O
. O

The O
PF B
( I
6 I
) I
( I
- I
) I
anion O
performs O
isotropic O
rotation O
in O
all O
three O
polymorphic O
crystals O
phases O
alpha O
, O
beta O
, O
and O
gamma O
as O
well O
as O
in O
the O
liquid O
state O
with O
a O
characteristic O
time O
scale O
that O
ranges O
from O
a O
few O
ps O
to O
a O
few O
hundred O
ps O
over O
a O
temperature O
range O
of O
180 O
- O
280 O
K O
. O

The O
rotational O
correlation O
time O
tau O
( O
c O
) O
for O
PF B
( I
6 I
) I
( I
- I
) I
rotation O
follows O
the O
sequence O
gamma O
- O
phase O
< O
alpha O
- O
phase O
= O
~ O
liquid O
< O
beta O
- O
phase O
. O

On O
the O
other O
hand O
, O
in O
the O
liquid O
state O
, O
all O
local O
motions O
in O
the O
cation O
as O
well O
as O
its O
global O
rotational O
reorientation O
are O
characterized O
by O
time O
scales O
that O
are O
slower O
compared O
to O
that O
for O
the O
PF B
( I
6 I
) I
( I
- I
) I
anion O
rotation O
. O

The O
time O
scale O
tau O
( O
c O
) O
and O
the O
activation O
energy O
of O
PF B
( I
6 I
) I
( I
- I
) I
rotation O
in O
this O
RTIL O
are O
found O
to O
be O
comparable O
with O
those O
observed O
in O
ordinary O
alkali O
and O
ammonium B
salts I
despite O
the O
large O
counterion O
size O
and O
low O
melting O
point O
of O
the O
former O
. O

The O
high O
sphericity O
of O
the O
PF B
( I
6 I
) I
( I
- I
) I
ion O
is O
hypothesized O
to O
play O
an O
important O
role O
in O
the O
decoupling O
of O
its O
rotational O
dynamics O
that O
appear O
to O
be O
practically O
independent O
of O
the O
averaged O
cation O
- O
anion O
interaction O
. O

Pretreatment O
of O
porcine O
skin O
was O
performed O
with O
ethanol B
( O
control O
vehicle O
) O
, O
decenoic B
acid I
, O
oleic B
acid I
, O
R B
- I
( I
+ I
) I
- I
limonene I
, O
and O
laurocapram B
( O
Azone B
( O
R O
) O
) O
( O
5 O
% O
in O
ethanol B
, O
w O
/ O
w O
, O
respectively O
) O
. O

The O
direct O
reaction O
between O
branched O
, O
racemic O
allylic B
alcohols I
and O
potassium B
alkenyltrifluorobora I
proceeded O
with O
high O
site O
selectivity O
and O
excellent O
enantioselectivity O
( O
up O
to O
99 O
% O
) O
mediated O
by O
an O
Ir B
- I
( I
P I
, I
olefin I
) I
complex O
. O

The O
C B
- I
H I
bonds O
of O
precise O
location O
of O
inert O
polymer O
surfaces O
were O
readily O
transferred O
to O
bromoalkyl B
initiator O
, O
followed O
by O
ATRP O
of O
2 B
- I
( I
dimethylamino I
) I
ethyl I
methacrylate I
( O
DMAEMA B
) O
and O
glycidyl B
methacrylate I
( O
GMA B
) O
, O
respectively O
, O
to O
produce O
the O
resultant O
patterned O
BOPP O
- O
g O
- O
P B
( I
DMAEMA I
) I
and O
BOPP O
- O
g O
- O
P B
( I
GMA I
) I
films O
. O

3 B
, I
4 I
- I
Methylenedioxy I
- I
methamphetamine I
induces O
in O
vivo O
regional O
up O
- O
regulation O
of O
central O
nicotinic O
receptors O
in O
rats O
and O
potentiates O
the O
regulatory O
effects O
of O
nicotine B
on O
these O
receptors O
. O

Recent O
work O
has O
demonstrated O
that O
the O
recreational O
drug O
3 B
, I
4 I
- I
methylenedioxy I
- I
methamphetamine I
( O
MDMA B
) O
has O
affinity O
for O
nAChR O
and O
also O
induces O
up O
- O
regulation O
of O
nAChR O
in O
PC O
12 O
cells O
. O

MDMA B
induced O
significant O
decreases O
in O
[ B
( I
3 I
) I
H I
] I
paroxetine I
binding O
in O
the O
cortex O
and O
hippocampus O
measured O
24h O
after O
the O
last O
dose O
and O
these O
decreases O
were O
not O
modified O
by O
the O
association O
with O
NIC B
. O

In O
the O
prefrontal O
cortex O
, O
NIC B
and O
MDMA B
each O
induced O
significant O
increases O
in O
[ B
( I
3 I
) I
H I
] I
epibatidine I
binding O
( O
29 O
. O
5 O
and O
34 O
. O
6 O
% O
, O
respectively O
) O
with O
respect O
to O
saline O
- O
treated O
rats O
, O
and O
these O
increases O
were O
significantly O
potentiated O
( O
up O
to O
72 O
. O
1 O
% O
) O
when O
the O
two O
drugs O
were O
associated O
. O

Also O
in O
this O
area O
, O
[ B
( I
3 I
) I
H I
] I
methyllycaconitine I
binding O
was O
increased O
a O
42 O
. O
1 O
% O
with O
NIC B
+ O
MDMA B
but O
not O
when O
they O
were O
given O
alone O
. O

In O
situ O
single O
- O
pass O
intestinal O
perfusions O
were O
employed O
( O
pH O
6 O
. O
5 O
x O
90 O
minutes O
) O
to O
assess O
the O
effective O
permeability O
( O
P O
( O
eff O
) O
) O
of O
100 O
mu O
M O
[ B
( I
3 I
) I
H I
] I
valacyclovir I
in O
wild O
- O
type O
and O
PepT1 O
knockout O
mice O
. O

To O
determine O
the O
absolute O
stereochemistry O
of O
the O
microbial O
product O
, O
we O
prepared O
( B
S I
) I
- I
2 I
- I
( I
4 I
- I
hydroxyphenyl I
) I
propionic I
acid I
from O
( B
S I
) I
- I
2 I
- I
phenylpropionic I
and O
concluded O
that O
the O
microbial O
product O
had O
an O
R O
- O
configuration O
by O
chiral O
HPLC O
analysis O
. O

Comparative O
formation O
of O
2 B
- I
amino I
- I
1 I
- I
methyl I
- I
6 I
- I
phenylimidazo I
[ I
4 I
, I
5 I
- I
b I
] I
pyridine I
( O
PhIP B
) O
in O
creatinine B
/ O
phenylalanine B
and O
creatinine B
/ O
phenylalanine B
/ O
4 B
- I
oxo I
- I
2 I
- I
nonenal I
reaction O
mixtures O
. O

The O
comparative O
formation O
of O
the O
heterocyclic O
aromatic O
amine O
2 B
- I
amino I
- I
1 I
- I
methyl I
- I
6 I
- I
phenylimidazo I
[ I
4 I
, I
5 I
- I
b I
] I
pyridine I
( O
PhIP B
) O
in O
both O
creatinine B
/ O
phenylalanine B
( O
CRN B
/ O
Phe B
) O
and O
creatinine B
/ O
phenylalanine B
/ O
4 B
- I
oxo I
- I
2 I
- I
nonenal I
( O
CRN B
/ O
Phe B
/ O
ON O
) O
systems O
was O
studied O
to O
analyse O
the O
ability O
of O
lipid O
- O
derived O
reactive O
carbonyls B
to O
promote O
PhIP B
formation O
. O

Aliphatic B
aldehydes I
such O
as O
hexanal B
, O
( B
E I
) I
- I
2 I
- I
octenal I
, O
and O
nonanal B
were O
produced O
as O
off O
- O
odours O
during O
storage O
. O

Tri B
- I
and I
diorganotin I
( I
IV I
) I
complexes O
of O
biologically O
important O
orotic B
acid I
: O
synthesis O
, O
spectroscopic O
studies O
, O
in O
vitro O
anti O
- O
cancer O
, O
DNA O
fragmentation O
, O
enzyme O
assays O
and O
in O
vivo O
anti O
- O
inflammatory O
activities O
. O

Radioreceptor O
binding O
assays O
showed O
a O
significant O
increase O
in O
alpha B
- I
amino I
- I
3 I
- I
hydroxy I
- I
5 I
- I
methyl I
- I
4 I
- I
isoxazole I
propionate I
and O
N B
- I
methyl I
- I
D I
- I
aspartate I
receptors O
density O
which O
was O
confirmed O
by O
immunohistochemical O
studies O
. O

Neu2000 B
[ O
2 B
- I
hydroxy I
- I
5 I
- I
( I
2 I
, I
3 I
, I
5 I
, I
6 I
- I
tetrafluoro I
- I
4 I
trifluoromethylbenzy I
) I
benzoic I
acid I
] O
is O
a O
dual O
- O
acting O
neuroprotective O
agent O
that O
functions O
both O
as O
a O
noncompetitive O
N B
- I
methyl I
- I
d I
- I
aspartate I
( O
NMDA O
) O
receptor O
antagonist O
and O
a O
free O
radical O
scavenger O
. O

The O
present O
review O
focuses O
on O
the O
synthesis O
and O
biological O
evaluation O
of O
polycyclic B
4 I
( I
3H I
) I
- I
quinazolinones I
containing O
fused O
aromatic O
or O
heteroaromatic O
rings O
. O

( B
R I
) I
- I
beta I
- I
lysine I
- O
modified O
elongation O
factor O
P O
functions O
in O
translation O
elongation O
. O

Post O
- O
translational O
modification O
of O
bacterial O
elongation O
factor O
P O
( O
EF O
- O
P O
) O
with O
( B
R I
) I
- I
beta I
- I
lysine I
at O
a O
conserved O
lysine O
residue O
activates O
the O
protein O
in O
vivo O
and O
increases O
puromycin O
reactivity O
of O
the O
ribosome O
in O
vitro O
. O

Investigation O
of O
hydroxyl B
- I
( I
beta I
) I
- I
lysyl I
- O
EF O
- O
P O
showed O
30 O
% O
increased O
puromycin B
reactivity O
but O
no O
differences O
in O
dipeptide O
synthesis O
rates O
when O
compared O
with O
the O
beta O
- O
lysylated O
form O
. O

A O
class O
of O
5 B
- I
nitro I
- I
2 I
- I
furancarboxylamides I
with O
potent O
trypanocidal O
activity O
against O
Trypanosoma O
brucei O
in O
vitro O
. O

In O
this O
study O
, O
we O
have O
synthesized O
a O
series O
of O
novel O
5 B
- I
nitro I
- I
2 I
- I
furancarboxylamides I
that O
show O
potent O
trypanocidal O
activity O
, O
~ O
1000 O
- O
fold O
more O
potent O
than O
nifurtimox B
against O
in O
vitro O
Trypanosoma O
brucei O
with O
very O
low O
cytotoxicity O
against O
human O
HeLa O
cells O
. O

This O
implies O
that O
our O
novel O
, O
relatively O
easy O
to O
synthesize O
and O
therefore O
cheap O
, O
5 B
- I
nitro I
- I
2 I
- I
furancarboxylamides I
are O
targeting O
a O
different O
, O
but O
still O
essential O
, O
biochemical O
process O
to O
those O
targeted O
by O
nifurtimox B
or O
its O
metabolites O
in O
the O
parasites O
. O

Induced O
expression O
of O
cytochrome O
P450 O
1A O
and O
NAD B
( I
P I
) I
H I
: O
quinone B
oxidoreductase O
determined O
at O
mRNA O
, O
protein O
, O
and O
enzyme O
activity O
levels O
in O
rats O
exposed O
to O
the O
carcinogenic O
azo B
dye O
1 B
- I
phenylazo I
- I
2 I
- I
naphthol I
( O
Sudan B
I I
) O
. O

Sudan B
I I
( O
1 B
- I
phenylazo I
- I
2 I
- I
hydroxynaphthol I
) O
is O
a O
suspected O
human O
carcinogen O
causing O
tumors O
in O
the O
livers O
and O
urinary O
bladders O
of O
rats O
, O
mice O
, O
and O
rabbits O
. O

ChE O
activity O
was O
measured O
with O
acetylthiocholine B
as O
substrate O
and O
CES O
activity O
was O
measured O
with O
four O
substrates O
: O
p B
- I
nitrophenyl I
acetate I
, O
p B
- I
nitrophenyl I
butyrate I
, O
1 B
- I
and I
2 I
- I
naphthyl I
acetate I
. O

cAMP B
- O
response O
element O
( O
CRE O
) O
- O
dependent O
induction O
of O
Per1 O
promoter O
activity O
in O
response O
to O
FSK B
in O
combination O
with O
phorbol B
12 I
- I
tetradecanoate I
13 I
- I
acetate I
was O
suppressed O
in O
cells O
that O
expressed O
high O
levels O
of O
AhR O
( O
c7 O
) O
compared O
with O
cells O
lacking O
functional O
AhR O
activity O
( O
c12 O
) O
. O

We O
show O
that O
UAAs O
inserted O
in O
the O
N B
- O
terminal O
domain O
of O
N B
- I
methyl I
- I
D I
- I
aspartate I
receptors O
( O
NMDARs O
) O
serve O
as O
photo O
- O
crosslinkers O
that O
lock O
the O
receptor O
in O
a O
discrete O
conformational O
state O
in O
response O
to O
UV O
photo O
treatment O
. O

CMT4B O
results O
from O
mutations O
in O
either O
myotubularin O
- O
related O
protein O
2 O
( O
MTMR2 O
; O
CMT4B1 O
) O
or O
MTMR13 O
( O
CMT4B2 O
) O
, O
phosphoinositide O
( O
PI O
) O
3 O
- O
phosphatases O
that O
dephosphorylate O
phosphatidylinositol B
3 I
- I
phosphate I
( O
PtdIns3P B
) O
and O
PtdIns B
( I
3 I
, I
5 I
) I
P2 I
, O
lipids O
which O
regulate O
endo O
- O
lysosomal O
membrane O
traffic O
. O

Treatment O
of O
3a O
with O
98 O
% O
H2SO4 B
yielded O
pancordine O
( O
10 O
) O
, O
which O
, O
upon O
catalytic O
hydrogenation O
, O
yielded O
( B
+ I
/ I
- I
) I
- I
wilsonirine I
. O

Drug O
disposition O
was O
characterized O
after O
intravenous O
infusion O
of O
[ B
( I
14 I
) I
C I
] I
LY2090314 I
to O
rats O
and O
dogs O
, O
and O
was O
related O
to O
available O
clinical O
data O
. O

Mechanistically O
, O
it O
was O
determined O
that O
the O
induced O
levels O
of O
GADD45 O
gamma O
mRNA O
resulting O
from O
( B
- I
) I
- I
xanthatin I
exposures O
were O
stabilized O
by O
coordinately O
produced O
ROS O
, O
and O
that O
the O
consequent O
induction O
of O
GADD45 O
gamma O
mRNA O
, O
GADD45 O
gamma O
protein O
and O
ROS O
generation O
were O
abrogated O
by O
co O
- O
treatment O
with O
N B
- I
acetyl I
- I
l I
- I
cysteine I
. O

Diminutive O
effect O
on O
T O
and O
B O
- O
cell O
proliferation O
of O
non O
- O
cytotoxic O
alpha B
- I
santonin I
derived O
1 B
, I
2 I
, I
3 I
- I
triazoles I
: O
a O
report O
. O

alpha B
- I
Santonin I
derived O
new O
series O
of O
1 B
, I
2 I
, I
3 I
- I
triazoles I
synthesized O
through O
Azide B
- I
Alkyne I
Huisgen O
1 O
, O
3 O
- O
dipolar O
cycloaddition O
reaction O
between O
substituted O
aryl B
azide I
and O
a O
propargylated B
alpha I
- I
desmotrosantonin I
were O
bio O
- O
evaluated O
for O
their O
diminutive O
effect O
on O
ConA O
induced O
T O
- O
cell O
and O
LPS O
induced O
B O
- O
cell O
proliferation O
. O

Although O
the O
levels O
of O
amino B
acid I
neurotransmitters O
, O
including O
glutamate B
, O
did O
not O
show O
marked O
alteration O
, O
the O
expression O
of O
the O
glutamatergic O
signaling O
pathway O
such O
as O
N B
- I
methyl I
- I
D I
- I
aspartate I
receptors O
, O
a B
- I
amino I
- I
3 I
- I
hydroxy I
- I
5 I
- I
methylisoxazole I
- I
4 I
- I
propionic I
acid I
receptor O
, O
calmodulin O
, O
Ca B
( I
2 I
+ I
) I
/ O
calmodulin O
- O
dependent O
protein O
kinases O
- O
II O
and O
cyclic B
adenosine I
monophosphate I
responsive O
element O
binding O
protein O
, O
was O
significantly O
reduced O
by O
TBT B
exposure O

Ex O
vivo O
samples O
of O
human O
oral O
mucosa O
were O
exposed O
to O
Pb B
or O
BaP B
, O
and O
immunohistochemical O
staining O
was O
performed O
to O
evaluate O
active O
caspase O
- O
3 O
, O
8 B
- I
epi I
- I
prostaglandin I
F2 I
alpha I
( O
8 B
- I
epi I
- I
PGF2a I
) O
, O
and O
3 B
- I
nitrotyrosine I
( O
3 B
- I
NT I
) O
. O

EMIQ O
increased O
liver O
levels O
of O
thiobarbituric B
acid I
- O
reactive O
substance O
and O
8 B
- I
hydroxydeoxyguanosin I
, O
and O
TUNEL O
( O
+ O
) O
apoptotic O
cells O
, O
death O
receptor O
5 O
( O
DR5 O
) O
( O
+ O
) O
cells O
and O
4 B
- I
hydroxy I
- I
2 I
- I
nonenal I
( O
+ O
) O
cells O
within O
GST O
- O
P O
( O
+ O
) O
foci O
. O

Synthesis O
of O
the O
6 B
- I
hydroxy I
- I
7 I
- I
methyl I
analog O
of O
typharin B
( O
8 B
- I
dihydroxy I
- I
3 I
- I
styryl I
- I
3 I
, I
4 I
- I
dihydroisocoumarin I
) O
isolated O
from O
the O
rhizomes O
of O
Typha O
capensis O
has O
been O
described O
. O

Compound O
1a O
, O
a O
structure O
based O
on O
3 B
- I
hydroxychromone I
bearing O
isothiazolidine B
- I
1 I
, I
1 I
- I
dione I
, O
was O
identified O
from O
chemical O
library O
as O
a O
highly O
potent O
GSK O
- O
3 O
inhibitor O
. O

Tri B
- I
o I
- I
cresyl I
- I
phosphate I
( O
TOCP B
) O
is O
a O
common O
additive O
in O
jet O
engine O
lubricants O
and O
hydraulic O
fluids O
suspected O
to O
have O
a O
role O
in O
aerotoxic O
syndrome O
in O
humans O
. O

Photoelectron O
imaging O
experiments O
and O
detailed O
calculations O
are O
conducted O
on O
Al B
( I
n I
) I
( I
- I
) I
clusters O
( O
n O
= O
3 O
- O
6 O
) O
and O
a O
calibration O
method O
is O
developed O
for O
connecting O
experimental O
observations O
of O
photoelectron O
angular O
distributions O
to O
theoretical O
predictions O
. O

The O
highest O
occupied O
molecular O
orbitals O
of O
these O
small O
aluminum B
clusters O
are O
found O
to O
contain O
varying O
degrees O
of O
s O
- O
p O
mixing O
, O
with O
Al B
( I
3 I
) I
( I
- I
) I
containing O
the O
" O
most O
hybridized O
" O
orbital O
and O
Al B
( I
4 I
) I
( I
- I
) I
containing O
the O
" O
least O
hybridized O
" O
orbital O
. O

The O
highest O
occupied O
molecular O
orbitals O
of O
these O
small O
aluminum B
clusters O
are O
found O
to O
contain O
varying O
degrees O
of O
s O
- O
p O
mixing O
, O
with O
Al B
( I
3 I
) I
( I
- I
) I
containing O
the O
" O
most O
hybridized O
" O
orbital O
and O
Al B
( I
4 I
) I
( I
- I
) I
containing O
the O
" O
least O
hybridized O
" O
orbital O
. O

A O
cobalt B
chlorin I
complex O
( O
Co B
( I
II I
) I
( I
Ch I
) I
) O
efficiently O
and O
selectively O
catalyzed O
two O
- O
electron O
reduction O
of O
dioxygen B
( O
O B
( I
2 I
) I
) O
by O
one O
- O
electron O
reductants O
( O
ferrocene B
derivatives O
) O
to O
produce O
hydrogen B
peroxide I
( O
H B
( I
2 I
) I
O I
( I
2 I
) I
) O
in O
the O
presence O
of O
perchloric B
acid I
( O
HClO B
( I
4 I
) I
) O
in O
benzonitrile B
( O
PhCN B
) O
at O
298 O
K O
. O

The O
catalytic O
reactivity O
of O
Co B
( I
II I
) I
( I
Ch I
) I
was O
much O
higher O
than O
that O
of O
a O
cobalt B
porphyrin I
complex O
( O
Co B
( I
II I
) I
( I
OEP I
) I
, O
OEP B
( I
2 I
- I
) I
= O
octaethylporphyrin B
dianion O
) O
, O
which O
is O
a O
typical O
porphyrinoid O
complex O
. O

The O
catalytic O
reactivity O
of O
Co B
( I
II I
) I
( I
Ch I
) I
was O
much O
higher O
than O
that O
of O
a O
cobalt B
porphyrin I
complex O
( O
Co B
( I
II I
) I
( I
OEP I
) I
, O
OEP B
( I
2 I
- I
) I
= O
octaethylporphyrin B
dianion O
) O
, O
which O
is O
a O
typical O
porphyrinoid O
complex O
. O

The O
two O
- O
electron O
reduction O
of O
O B
( I
2 I
) I
by O
1 B
, I
1 I
' I
- I
dibromoferrocene I
( O
Br B
( I
2 I
) I
Fc I
) O
was O
catalyzed O
by O
Co B
( I
II I
) I
( I
Ch I
) I
, O
whereas O
virtually O
no O
reduction O
of O
O B
( I
2 I
) I
occurred O
with O
Co B
( I
II I
) I
( I
OEP I
) I
. O

The O
two O
- O
electron O
reduction O
of O
O B
( I
2 I
) I
by O
1 B
, I
1 I
' I
- I
dibromoferrocene I
( O
Br B
( I
2 I
) I
Fc I
) O
was O
catalyzed O
by O
Co B
( I
II I
) I
( I
Ch I
) I
, O
whereas O
virtually O
no O
reduction O
of O
O B
( I
2 I
) I
occurred O
with O
Co B
( I
II I
) I
( I
OEP I
) I
. O

In O
addition O
, O
Co B
( I
II I
) I
( I
Ch I
) I
is O
more O
stable O
than O
Co B
( I
II I
) I
( I
OEP I
) I
, O
where O
the O
catalytic O
turnover O
number O
( O
TON O
) O
of O
the O
two O
- O
electron O
reduction O
of O
O B
( I
2 I
) I
catalyzed O
by O
Co B
( I
II I
) I
( I
Ch I
) I
exceeded O
30000 O
. O

In O
addition O
, O
Co B
( I
II I
) I
( I
Ch I
) I
is O
more O
stable O
than O
Co B
( I
II I
) I
( I
OEP I
) I
, O
where O
the O
catalytic O
turnover O
number O
( O
TON O
) O
of O
the O
two O
- O
electron O
reduction O
of O
O B
( I
2 I
) I
catalyzed O
by O
Co B
( I
II I
) I
( I
Ch I
) I
exceeded O
30000 O
. O

In O
addition O
, O
Co B
( I
II I
) I
( I
Ch I
) I
is O
more O
stable O
than O
Co B
( I
II I
) I
( I
OEP I
) I
, O
where O
the O
catalytic O
turnover O
number O
( O
TON O
) O
of O
the O
two O
- O
electron O
reduction O
of O
O B
( I
2 I
) I
catalyzed O
by O
Co B
( I
II I
) I
( I
Ch I
) I
exceeded O
30000 O
. O

The O
detailed O
kinetic O
studies O
have O
revealed O
that O
the O
rate O
- O
determining O
step O
in O
the O
catalytic O
cycle O
is O
the O
proton O
- O
coupled O
electron O
transfer O
reduction O
of O
O B
( I
2 I
) I
with O
the O
protonated O
Co B
( I
II I
) I
( I
Ch I
) I
( O
[ B
Co I
( I
II I
) I
( I
ChH I
) I
] I
( I
+ I
) I
) O
that O
is O
produced O
by O
facile O
electron O
- O
transfer O
reduction O
of O
[ B
Co I
( I
III I
) I
( I
ChH I
) I
] I
( I
2 I
+ I
) I
by O
ferrocene B
derivative O
in O
the O
presence O
of O
HClO B
( I
4 I
) I
. O

The O
synthesis O
and O
reversible O
addition O
- O
fragmentation O
chain O
transfer O
( O
RAFT O
) O
polymerization O
of O
amino B
acid I
- O
based O
chiral O
monomers O
, O
namely O
Boc B
- I
L I
- I
leucine I
methacryloyloxyethyl I
ester I
( O
Boc B
- I
L I
- I
Leu I
- I
HEMA I
, O
1a O
) O
, O
Boc B
- I
L I
- I
leucine I
acryloyloxyethyl I
ester I
( O
Boc B
- I
L I
- I
Leu I
- I
HEA I
, O
1b O
) O
, O
Boc B
- I
L I
- I
isoleucine I
methacryloyloxyethyl I
ester I
( O
Boc B
- I
L I
- I

The O
synthesis O
and O
reversible O
addition O
- O
fragmentation O
chain O
transfer O
( O
RAFT O
) O
polymerization O
of O
amino B
acid I
- O
based O
chiral O
monomers O
, O
namely O
Boc B
- I
L I
- I
leucine I
methacryloyloxyethyl I
ester I
( O
Boc B
- I
L I
- I
Leu I
- I
HEMA I
, O
1a O
) O
, O
Boc B
- I
L I
- I
leucine I
acryloyloxyethyl I
ester I
( O
Boc B
- I
L I
- I
Leu I
- I
HEA I
, O
1b O
) O
, O
Boc B
- I
L I
- I
isoleucine I
methacryloyloxyethyl I
ester I
( O
Boc B
- I
L I
- I

The O
synthesis O
and O
reversible O
addition O
- O
fragmentation O
chain O
transfer O
( O
RAFT O
) O
polymerization O
of O
amino B
acid I
- O
based O
chiral O
monomers O
, O
namely O
Boc B
- I
L I
- I
leucine I
methacryloyloxyethyl I
ester I
( O
Boc B
- I
L I
- I
Leu I
- I
HEMA I
, O
1a O
) O
, O
Boc B
- I
L I
- I
leucine I
acryloyloxyethyl I
ester I
( O
Boc B
- I
L I
- I
Leu I
- I
HEA I
, O
1b O
) O
, O
Boc B
- I
L I
- I
isoleucine I
methacryloyloxyethyl I
ester I
( O
Boc B
- I
L I
- I

The O
synthesis O
and O
reversible O
addition O
- O
fragmentation O
chain O
transfer O
( O
RAFT O
) O
polymerization O
of O
amino B
acid I
- O
based O
chiral O
monomers O
, O
namely O
Boc B
- I
L I
- I
leucine I
methacryloyloxyethyl I
ester I
( O
Boc B
- I
L I
- I
Leu I
- I
HEMA I
, O
1a O
) O
, O
Boc B
- I
L I
- I
leucine I
acryloyloxyethyl I
ester I
( O
Boc B
- I
L I
- I
Leu I
- I
HEA I
, O
1b O
) O
, O
Boc B
- I
L I
- I
isoleucine I
methacryloyloxyethyl I
ester I
( O
Boc B
- I
L I
- I

The O
synthesis O
and O
reversible O
addition O
- O
fragmentation O
chain O
transfer O
( O
RAFT O
) O
polymerization O
of O
amino B
acid I
- O
based O
chiral O
monomers O
, O
namely O
Boc B
- I
L I
- I
leucine I
methacryloyloxyethyl I
ester I
( O
Boc B
- I
L I
- I
Leu I
- I
HEMA I
, O
1a O
) O
, O
Boc B
- I
L I
- I
leucine I
acryloyloxyethyl I
ester I
( O
Boc B
- I
L I
- I
Leu I
- I
HEA I
, O
1b O
) O
, O
Boc B
- I
L I
- I
isoleucine I
methacryloyloxyethyl I
ester I
( O
Boc B
- I
L I
- I

Ile I
- I
HEMA I
, O
1c O
) O
, O
and O
Boc B
- I
L I
- I
isoleucine I
acryloyloxyethyl I
ester I
( O
Boc B
- I
L I
- I
Ile I
- I
HEA I
, O
1d O
) O
, O
are O
reported O
. O

In O
effect O
, O
hydration O
at O
one O
of O
the O
carbonyl B
functions O
effectively O
eliminates O
the O
low O
- O
energy O
( O
3 O
) O
MLCT O
( O
SQ O
) O
state O
( O
Ru B
( I
III I
) I
phen I
- I
semiquinone I
radical O
anion O
) O
as O
the O
predominant O
nonradiative O
decay O
pathway O
. O

Leu B
- I
Gly I
- I
NH2 I
and O
the O
( B
S I
) I
- I
alpha I
- I
Tfm I
- I
proline I
. O

The O
analgesic O
effect O
of O
the O
CF3 B
- I
( I
MIF I
- I
1 I
) I
2 O
has O
been O
evaluated O
in O
vivo O
on O
rat O
model O
by O
paw O
pressure O
( O
PP O
) O
and O
hot O
plate O
( O
HP O
) O
tests O
and O
compared O
to O
the O
native O
peptide O
MIF B
- I
1 I
. O

Highest O
analgesic O
effect O
was O
observed O
with O
CF3 B
- I
( I
MIF I
- I
1 I
) I
2 O
only O
in O
PP O
test O
. O

The O
results O
are O
in O
favor O
of O
a O
participation O
of O
both O
system O
since O
pretreatment O
, O
20 O
min O
before O
injection O
of O
the O
CF3 B
- I
( I
MIF I
- I
1 I
) I
2 O
, O
with O
the O
non O
- O
competitive O
antagonist O
of O
opiate O
receptors O
naloxone B
, O
the O
nitric B
oxide I
synthase O
( O
NOS O
) O
inhibitor O
l B
- I
N I
( I
G I
) I
- I
nitroarginine I
ester I
( O
l B
- I
NAME I
) O
or O
the O
nitric B
oxide I
( O
NO B
) O
donor O
l B
- I
arginine I
( O
l B
- I
Arg I
) O
significantly O
decreased O
the O
pain O
perception O
in O
PP O
and O
HP O
tests O
. O

A O
TK O
/ O
TD O
model O
was O
developed O
that O
simulates O
the O
effect O
on O
growth O
of O
the O
green O
algae O
Scenedesmus O
vacuolatus O
continuously O
exposed O
to O
the O
model O
chemicals O
norflurazon B
, O
triclosan B
, O
and O
N B
- I
phenyl I
- I
2 I
- I
naphthylamine I
. O

PEG B
- O
Modified O
Macroporous O
Poly B
( I
Glycidyl I
Methacrylate I
) I
and O
Poly B
( I
2 I
- I
Hydroxyethyl I
Methacrylate I
) I
Microspheres O
to O
Reduce O
Non O
- O
Specific O
Protein O
Adsorption O
. O

To O
minimize O
non O
- O
specific O
protein O
adsorption O
on O
macroporous O
poly B
( I
glycidyl I
methacrylate I
) I
and O
poly B
( I
2 I
- I
hydroxyethyl I
methacrylate I
) I
microspheres O
containing O
amino B
and O
/ O
or O
carboxyl B
groups O
, O
the O
microspheres O
are O
coated O
with O
alpha B
, I
omega I
- I
bis I
- I
carboxy I
poly I
( I
ethylene I
glycol I
) I
and O
amino B
- O
terminated O
poly B
( I
ethylene I
glycol I
- I
co I
- I
propylene I
glycol I
) I
or O
alpha B
- I
methoxy I
- I
omega I
- I
amino I

The O
colloidal O
particles O
consist O
of O
a O
solid O
polystyrene B
core O
and O
a O
cross O
- O
linked O
poly B
- I
N I
- I
( I
isopropylacrylamide I
) I
shell O
with O
embedded O
crystalline O
titanium B
dioxide I
( O
TiO B
( I
2 I
) I
) O
nanoparticles O
( O
d O
= O
6 O
+ O
/ O
- O
3 O
nm O
) O
. O

We O
performed O
a O
combinatorial O
study O
to O
examine O
the O
effects O
of O
polymer O
chemistry O
and O
order O
of O
deposition O
of O
poly B
( I
beta I
- I
amino I
) I
esters I
on O
protein O
release O
kinetics O
under O
81 O
LBL O
assembly O
conditions O
. O

Six O
new O
9 B
, I
19 I
- I
cycloartane I
triterpene I
glycosides I
, O
heracleifolinosides B
A I
- I
F I
( O
1 O
- O
6 O
) O
, O
and O
one O
new O
chromone O
, O
norkhelloside B
( O
7 O
) O
, O
were O
isolated O
from O
the O
rhizome O
of O
Cimicifuga O
heracleifolia O
, O
together O
with O
15 O
known O
compounds O
( O
8 O
- O
22 O
) O
. O

Heating O
these O
products O
within O
the O
used O
CuCl B
flux O
( O
mp O
= O
430 O
degrees O
C O
) O
to O
450 O
degrees O
C O
for O
30 O
min O
yields O
~ O
4 O
- O
12 O
nm O
Cu B
2 I
Nb I
8 I
O I
2 I
1 I
crystalline O
nanoparticles O
, O
and O
for O
a O
heating O
time O
of O
24 O
h O
yields O
mu O
m O
- O
sized O
, O
rod O
- O
shaped O
crystals O
. O

The O
p O
- O
type O
nature O
of O
the O
Cu B
2 I
Nb I
8 I
O I
2 I
1 I
particles O
was O
confirmed O
in O
photoelectrochemical O
measurements O
on O
polycrystalline O
films O
that O
show O
a O
strong O
photocathodic O
current O
under O
visible O
- O
light O
irradiation O
in O
aqueous O
solutions O
. O

Synthesis O
, O
quantitative O
structure O
- O
activity O
relationship O
and O
biological O
evaluation O
of O
1 B
, I
3 I
, I
4 I
- I
oxadiazole I
derivatives O
possessing O
diphenylamine B
moiety O
as O
potential O
anticancer O
agents O
. O

The O
alpha O
- O
subunit O
of O
tryptophan B
synthase O
( O
alpha O
TS O
) O
catalyzes O
the O
conversion O
of O
indole B
- I
3 I
- I
glycerol I
phosphate I
to O
d B
- I
glyceraldehyde I
- I
3 I
- I
phosphate I
and O
indole B
. O

This O
compound O
, O
although O
exhibiting O
modest O
affinity O
( O
K O
( O
i O
) O
= O
2 O
. O
24 O
mu O
M O
) O
for O
the O
[ B
( I
3 I
) I
H I
] I
N I
- I
methylscopolamine I
binding O
site O
on O
the O
M O
( O
5 O
) O
receptor O
, O
is O
potent O
( O
IC O
( O
50 O
) O
= O
0 O
. O
45 O
nM O
) O
in O
inhibiting O
oxotremorine B
- O
evoked O
[ B
( I
3 I
) I
H I
] I
DA I
release O
from O
rat O
striatal O
slices O
. O

Next O
, O
we O
examined O
the O
impact O
produced O
on O
the O
same O
abilities O
by O
intra O
- O
VS O
infusion O
of O
ineffective O
doses O
of O
amphetamine B
( O
0 O
. O
3 O
mu O
g O
/ O
side O
) O
in O
association O
with O
N B
- I
methyl I
- I
D I
- I
aspartate I
( O
NMDA B
) O
( O
3 O
. O
125 O
ng O
/ O
side O
) O
or O
alpha B
- I
amino I
- I
3 I
- I
hydroxy I
- I
5 I
- I
methylisoxazole I
- I
4 I
- I
propionic I
acid I
( O
AMPA B
) O
( O
0 O
. O
25 O
ng O
/ O
side O
) O
receptor O
antagonist O
. O

We O
found O
that O
Dex B
induced O
Mig6 O
and O
decreased O
[ B
( I
3 I
) I
H I
] I
thymidine I
incorporation O
, O
an O
index O
of O
cellular O
replication O
, O
in O
mouse O
, O
rat O
, O
and O
human O
islets O
. O

An O
inorganic O
( O
sodium B
selenite I
, O
Na2SeO3 B
) O
and O
organic O
( O
selenocysteine B
, O
Cys B
- I
Se I
- I
Se I
- I
Cys I
) O
selenocompound O
have O
been O
used O
as O
Se B
sources O
. O

Diclofenac B
- I
beta I
- I
d I
- I
glucuronide I
was O
used O
to O
explore O
potential O
time O
- O
dependent O
inactivation O
. O

Results O
: O
The O
chemical O
stability O
half O
- O
life O
values O
for O
CGP B
47292 I
- I
beta I
- I
d I
- I
glucuronide I
, O
diclofenac B
- I
beta I
- I
d I
- I
glucuronide I
, O
( B
R I
) I
- I
naproxen I
- I
beta I
- I
d I
- I
glucuronide I
, O
( B
S I
) I
- I
naproxen I
- I
beta I
- I
d I
- I
glucuronide I
, O
ibuprofen B
- I
beta I
- I
d I
- I
glucuronide I
( I
racemic I
) I
, O
clopidogrel B
- I
beta I
- I
d I
- I
glucuronide I
, O
and O
valproate B
- I
beta I
- I
d I
- I

Results O
: O
The O
chemical O
stability O
half O
- O
life O
values O
for O
CGP B
47292 I
- I
beta I
- I
d I
- I
glucuronide I
, O
diclofenac B
- I
beta I
- I
d I
- I
glucuronide I
, O
( B
R I
) I
- I
naproxen I
- I
beta I
- I
d I
- I
glucuronide I
, O
( B
S I
) I
- I
naproxen I
- I
beta I
- I
d I
- I
glucuronide I
, O
ibuprofen B
- I
beta I
- I
d I
- I
glucuronide I
( I
racemic I
) I
, O
clopidogrel B
- I
beta I
- I
d I
- I
glucuronide I
, O
and O
valproate B
- I
beta I
- I
d I
- I

Diclofenac B
- I
beta I
- I
d I
- I
glucuronide I
, O
clopidogrel B
- I
beta I
- I
d I
- I
glucuronide I
, O
ibuprofen B
- I
beta I
- I
d I
- I
glucuronide I
, O
( B
R I
) I
- I
naproxen I
- I
beta I
- I
d I
- I
glucuronide I
, O
and O
( B
S I
) I
- I
naproxen I
- I
beta I
- I
d I
- I
glucuronide I
selectively O
inhibited O
hCES1 O
, O
with O
Ki O
values O
of O
4 O
. O
32 O
+ O
/ O
- O
0 O
. O
47 O
, O
24 O
. O
8 O
+ O
/ O
- O
4 O
. O
2 O
, O
355 O
+ O
/ O
- O
38 O
, O

Diclofenac B
- I
beta I
- I
d I
- I
glucuronide I
, O
clopidogrel B
- I
beta I
- I
d I
- I
glucuronide I
, O
ibuprofen B
- I
beta I
- I
d I
- I
glucuronide I
, O
( B
R I
) I
- I
naproxen I
- I
beta I
- I
d I
- I
glucuronide I
, O
and O
( B
S I
) I
- I
naproxen I
- I
beta I
- I
d I
- I
glucuronide I
selectively O
inhibited O
hCES1 O
, O
with O
Ki O
values O
of O
4 O
. O
32 O
+ O
/ O
- O
0 O
. O
47 O
, O
24 O
. O
8 O
+ O
/ O
- O
4 O
. O
2 O
, O
355 O
+ O
/ O
- O
38 O
, O

Valproate B
- I
beta I
- I
d I
- I
glucuronide I
and O
CGP B
47292 I
- I
beta I
- I
d I
- I
glucuronide I
did O
not O
inhibit O
either O
hCES O
. O

Time O
- O
dependent O
inactivation O
of O
hCES1 O
by O
diclofenac B
- I
beta I
- I
d I
- I
glucuronide I
was O
not O
observed O
. O

The O
supramolecular O
host O
assembly O
[ B
Ga4L6 I
] I
( I
12 I
- I
) I
[ O
1 O
; O
L O
= O
1 B
, I
5 I
- I
bis I
( I
2 I
, I
3 I
- I
dihydroxybenzamido I
) I
naphthalene I
] O
contains O
a O
flexible O
, O
hydrophobic O
interior O
cavity O
that O
can O
encapsulate O
cationic O
guest O
molecules O
and O
catalyze O
a O
variety O
of O
chemical O
transformations O
. O

Adsorption O
of O
an O
in O
- O
house O
synthesized O
organic O
- O
inorganic O
Al B
( I
OH I
) I
3 I
- I
PAM I
( O
Al B
- I
PAM I
) O
as O
an O
example O
of O
cationic O
hybrid O
PAM B
and O
a O
commercially O
available O
partially O
hydrolyzed O
polyacrylamide B
( O
MF1011 B
) O
as O
an O
example O
of O
anionic B
PAM I
was O
studied O
. O

Model O
Pt B
( I
n I
) I
/ O
glassy B
carbon I
electrodes O
( O
Pt B
( I
n I
) I
/ O
GCE O
) O
were O
prepared O
by O
deposition O
of O
mass O
- O
selected O
Pt B
( I
n I
) I
( I
+ I
) I
( O
n O
< O
= O
11 O
) O
on O
GCE O
substrates O
in O
ultrahigh O
vacuum O
. O

Utilizing O
tin B
( I
II I
) I
bis I
( I
2 I
- I
ethylhexanoate I
) I
, O
aluminum B
salan I
, O
and O
aluminum B
salen I
catalysts O
, O
the O
copolymers O
were O
synthesized O
through O
the O
ring O
- O
opening O
polymerization O
of O
d O
- O
, O
l O
- O
, O
rac O
- O
, O
or O
a O
blend O
of O
l B
- I
and I
rac I
- I
lactide I
using O
monomethoxy B
- I
poly I
( I
ethylene I
glycol I
) I
as O
a O
macroinitiator O
. O

H2O2 B
inhibits O
the O
[ B
( I
3 I
) I
H I
] I
carnitine I
/ O
carnitine B
antiport O
catalysed O
by O
the O
mitochondrial O
carnitine B
/ O
acylcarnitine B
transporter O
reconstituted O
in O
proteoliposomes O
. O

Pyrogallol B
- O
related O
chemicals O
and O
tannins B
are O
present O
in O
dietary O
sources O
and O
individually O
produced O
strong O
activity O
: O
pyrogallol B
( O
30 O
x O
) O
, O
3 B
- I
methoxycatechol I
( O
25 O
x O
) O
, O
gallic B
acid I
( O
21 O
x O
) O
, O
and O
1 B
, I
2 I
, I
4 I
- I
benzenetriol I
( O
21 O
x O
) O
. O

The O
antibody O
was O
raised O
in O
rabbits O
against O
11 B
- I
KT I
- I
3 I
- I
CMO I
: O
bovine O
serum O
albumin O
with O
biotinylated B
11 I
- I
KT I
as O
a O
label O
. O

The O
most O
potent O
N3 O
- O
substituent O
was O
5 B
- I
chlorothiophene I
- I
2 I
- I
sulfonamide I
. O

Boiling O
of O
peeled O
tubers O
decreased O
contents O
of O
total O
glycoalkaloids B
( O
alpha B
- I
chaconine I
and I
alpha I
- I
solanine I
) O
and O
appeared O
as O
the O
most O
favourable O
among O
the O
three O
tested O
methods O
. O

Water O
- O
soluble O
apple O
peel O
polysaccharides O
( O
APP O
) O
and O
apple O
flesh O
polysaccharides O
( O
AFP O
) O
were O
isolated O
from O
Pink O
Lady O
fruits O
, O
and O
their O
in O
vitro O
antioxidant O
capacities O
were O
characterised O
by O
DPPH B
( O
) O
, O
HO B
( O
) O
, O
and O
O B
( I
2 I
) I
( I
- I
) I
systems O
, O
and O
ferric B
- O
reducing O
antioxidant O
power O
assay O
. O

With O
controlled O
parameters O
, O
the O
product O
was O
mainly O
composed O
of O
mono B
- I
and I
di I
- I
glucosylated I
stevioside I
while O
the O
highest O
stevioside B
conversion O
reached O
77 O
. O
11 O
% O
. O

We O
analyzed O
the O
association O
of O
serum O
vitamin B
D I
level O
assessed O
by O
25 B
- I
hydroxyvitamin I
D I
( I
3 I
) I
{ O
25 B
( I
OH I
) I
D I
( I
3 I
) I
} O
with O
nonalcoholic O
fatty O
liver O
disease O
( O
NAFLD O
) O
in O
apparently O
healthy O
men O
. O

Based O
on O
docking O
studies O
we O
evaluated O
in O
a O
[ B
( I
3 I
) I
H I
] I
pentazocine I
binding O
assay O
an O
oxa B
- I
PCU I
, O
NGP1 B
- I
01 I
( O
IC50 O
= O
1 O
. O
78 O
mu O
M O
) O
and O
its O
phenethyl B
derivative O
( O
IC50 O
= O
1 O
. O
54 O
mu O
M O
) O
. O

Metabolism O
of O
profenofos B
to O
4 B
- I
bromo I
- I
2 I
- I
chlorophenol I
, O
a O
specific O
and O
sensitive O
exposure O
biomarker O
. O

Profenofos B
is O
known O
to O
be O
detoxified O
to O
the O
biologically O
inactive O
metabolite O
, O
4 B
- I
bromo I
- I
2 I
- I
chlorophenol I
( O
BCP B
) O
; O
however O
, O
limited O
data O
are O
available O
regarding O
the O
use O
of O
urinary O
BCP B
as O
an O
exposure O
biomarker O
in O
humans O
. O

Two O
new O
coumarin B
glycosides I
, O
namely O
nitensosides B
A I
- I
B I
( O
1 O
- O
2 O
) O
, O
together O
with O
six O
known O
compounds O
, O
scopolin B
( O
3 O
) O
, O
5 B
, I
6 I
, I
7 I
- I
trimethoxycoumarin I
( O
4 O
) O
, O
d B
- I
calycanthine I
( O
5 O
) O
, O
calycanthoside B
( O
6 O
) O
, O
xeroboside B
( O
7 O
) O
, O
and O
scopoletin B
( O
8 O
) O
, O
were O
isolated O
from O
Chimonanthus O
nitens O
. O

In O
an O
attempt O
to O
overcome O
these O
problems O
, O
LiNi0 B
. I
62Co0 I
. I
14Mn0 I
. I
24O2 I
cathode O
material O
with O
pillar O
layers O
in O
which O
Ni B
( I
2 I
+ I
) I
ions O
were O
resided O
in O
Li B
slabs O
near O
the O
surface O
having O
a O
thickness O
of O
~ O
10 O
nm O
was O
prepared O
using O
a O
polyvinylpyrrolidone B
( O
PVP B
) O
functionalized O
Mn B
precursor O
coating O
on O
Ni0 B
. I
7Co0 I
. I
15Mn0 I
. I
15 I
( I
OH I
) I
2 I
. O

In O
addition O
, O
the O
amount O
of O
heat O
generation O
was O
decreased O
by O
40 O
% O
, O
compared O
to O
LiNi0 B
. I
70Co0 I
. I
15Mn0 I
. I
15O2 I
. O

A O
block O
/ O
homo O
- O
mixed O
polyplex O
micelle O
, O
comprising O
of O
cationic O
homo O
polymer O
: O
poly B
{ I
N I
' I
- I
[ I
N I
- I
( I
2 I
- I
aminoethyl I
) I
- I
2 I
- I
aminoethyl I
] I
aspartamide I
} I
P B
[ I
Asp I
( I
DET I
) I
] I
and O
block O
copolymer O
: O
polyethylene B
glycol I
( B
PEG I
) I
- I
b I
- I
P I
[ I
Asp I
( I
DET I
) I
] I
, O
has O
been O
reported O
to O
exhibit O
the O
efficient O
transgene O
expression O
in O
vivo O
by O
intratracheal O
and O
systemic O
administration O
. O

Nine O
out O
of O
fifteen O
2 B
- I
( I
1 I
- I
piperazinyl I
) I
derivatives O
( O
6g O
- O
o O
) O
showed O
good O
inhibitory O
properties O
towards O
all O
the O
platelet O
aggregation O
agonists O
used O
. O

The O
absolute O
configuration O
( O
AC O
) O
of O
the O
bioactive O
metabolites O
phyllostin B
( O
1 O
) O
and O
scytolide B
( O
2 O
) O
, O
two O
hexahydro B
- I
1 I
, I
4 I
- I
benzodioxines I
produced O
by O
Phyllosticta O
cirsii O
, O
and O
oxysporone B
( O
3 O
) O
, O
a O
dihydrofuropyranone B
recently O
isolated O
from O
a O
strain O
of O
Diplodia O
africana O
, O
has O
been O
assigned O
by O
computational O
analysis O
of O
their O
optical O
rotatory O
dispersion O
( O
ORD O
) O
, O
electronic O
circular O
dichroism O
( O
ECD O
) O
, O
and O
vibrational O
circular O

Correlation O
between O
structural O
, O
spectroscopic O
, O
and O
reactivity O
properties O
within O
a O
series O
of O
structurally O
analogous O
metastable O
manganese B
( I
III I
) I
- I
alkylperoxo I
complexes I
. O

By O
employment O
of O
( B
R I
) I
- I
2 I
- I
amino I
- I
2 I
- I
( I
4 I
- I
methoxyphenyl I
) I
ethanol I
as O
a O
chiral O
auxiliary O
, O
( B
2R I
) I
- I
IKM I
- I
159 I
and O
the O
( O
2S O
) O
- O
counterpart O
were O
successfully O
synthesized O
in O
0 O
. O
70 O
% O
and O
1 O
. O
5 O
% O
yields O
, O
respectively O
, O
over O
a O
total O
of O
18 O
steps O
. O

Both O
behavioral O
and O
electrophysiological O
assays O
showed O
that O
the O
biological O
activity O
observed O
for O
the O
racemic O
mixture O
was O
reproduced O
only O
with O
( B
2R I
) I
- I
IKM I
- I
159 I
, O
whereas O
the O
( O
2S O
) O
- O
counterpart O
was O
inactive O
in O
both O
assays O
. O

Racemic B
IKM I
- I
159 I
was O
crystallized O
with O
the O
ligand O
- O
binding O
domain O
of O
GluA2 O
, O
and O
the O
structure O
revealed O
a O
complex O
containing O
( B
2R I
) I
- I
IKM I
- I
159 I
at O
the O
glutamate O
binding O
site O
. O

( B
2R I
) I
- I
IKM I
- I
159 I
locks O
the O
GluA2 O
in O
an O
open O
form O
, O
consistent O
with O
a O
pharmacological O
action O
as O
competitive O
antagonist O
of O
AMPA O
receptors O
. O

Human O
cytochrome O
P450 O
( O
P450 O
) O
2A13 O
was O
found O
to O
interact O
with O
several O
polycyclic B
aromatic I
hydrocarbons I
( O
PAHs B
) O
to O
produce O
Type O
I O
binding O
spectra O
, O
including O
acenaphthene B
, O
acenaphthylene B
, O
benzo B
[ I
c I
] I
phenanthrene I
, O
fluoranthene B
, O
fluoranthene B
- I
2 I
, I
3 I
- I
diol I
, O
and O
1 B
- I
nitropyrene I
. O

P450 O
2A6 O
also O
interacted O
with O
acenaphthene B
and O
acenaphthylene B
, O
but O
not O
with O
fluoranthene B
, O
fluoranthene B
- I
2 I
, I
3 I
- I
diol I
, O
or O
1 B
- I
nitropyrene I
. O

P450 O
1B1 O
is O
well O
- O
known O
to O
oxidize O
many O
carcinogenic O
PAHs B
, O
and O
we O
found O
that O
several O
PAHs B
( O
i O
. O
e O
. O
, O
7 B
, I
12 I
- I
dimethylbenz I
[ I
a I
] I
anthracene I
, O
7 B
, I
12 I
- I
dimethylbenz I
[ I
a I
] I
anthracene I
- I
5 I
, I
6 I
- I
diol I
, O
benzo B
[ I
c I
] I
phenanthrene I
, O
fluoranthene B
, O
fluoranthene B
- I
2 I
, I
3 I
- I
diol I
, O
5 B
- I
methylchrysene I
, O
benz B
[ I
a I
] I
pyrene I
- I
4 I
, I
5 I
- I

We O
observed O
changes O
in O
FA O
composition O
that O
predominantly O
involved O
increases O
in O
FA B
methyl I
esters I
( O
FAMEs B
) O
, O
mono B
- I
and I
poly I
- I
unsaturated I
FA I
( O
MUFA B
and O
PUFA B
) O
and O
a O
decrease O
in O
n O
- O
3 O
/ O
n O
- O
6 O
PUFA B
ratio O
by O
both O
PFOA B
and O
PFOS B
. O

Three O
new O
orcinol B
( O
3 B
- I
hydroxy I
- I
5 I
- I
methylphenol I
) O
- O
conjugated O
hydrolysable O
tannins B
, O
together O
with O
two O
known O
compounds O
were O
isolated O
from O
the O
leaves O
of O
Cleyera O
japonica O
( O
CJ O
) O
, O
and O
have O
been O
tentatively O
named O
cleyeratannin B
A I
( O
1 O
) O
, O
cleyeratannin B
B I
( O
2 O
) O
and O
cleyeratannin B
C I
( O
3 O
) O
. O

1 B
, I
3 I
, I
4 I
- I
thiadiazole I
and O
its O
derivatives O
: O
a O
review O
on O
recent O
progress O
in O
biological O
activities O
. O

The O
1 B
, I
3 I
, I
4 I
- I
thiadiazole I
nucleus O
is O
one O
of O
the O
most O
important O
and O
well O
- O
known O
heterocyclic O
nuclei O
, O
which O
is O
a O
common O
and O
integral O
feature O
of O
a O
variety O
of O
natural O
products O
and O
medicinal O
agents O
. O

These O
fatty B
acids I
included O
jacaric B
and I
punicic I
acid I
found O
in O
jacaranda O
and O
pomegranate O
seed O
oil O
, O
respectively O
, O
three O
octadecatrienoic O
geometric O
isomers O
( O
alpha B
- I
and I
beta I
- I
calendic I
and I
catalpic I
acid I
) O
and O
two O
mono B
- I
unsaturated I
C I
- I
18 I
fatty I
acids I
( O
trans B
- I
and I
cis I
- I
vaccenic I
acid I
) O
. O

The O
approved O
treatments O
for O
Alzheimer O
' O
s O
disease O
( O
AD O
) O
exploit O
mainly O
a O
symptomatic O
approach O
based O
on O
the O
use O
of O
cholinesterase O
inhibitors O
or O
N B
- I
methyl I
- I
d I
- I
aspartate I
( O
NMDA B
) O
receptor O
antagonists O
. O

The O
leading O
cyclic B
polyamine I
disulfide I
was O
shown O
to O
be O
the O
spermine B
tetra I
- I
amine I
disulfide I
( O
TetraN B
- I
3 I
, I
4 I
, I
3 I
) O
. O

Rational O
design O
, O
synthesis O
and O
QSAR O
study O
of O
vasorelaxant O
active O
3 B
- I
pyridinecarbonitrile I
incorporating O
1H B
- I
benzimidazol I
- I
2 I
- I
yl I
function O
. O

A O
variety O
of O
2 B
- I
alkoxy I
- I
4 I
- I
aryl I
- I
6 I
- I
( I
1H I
- I
benzimidazol I
- I
2 I
- I
yl I
) I
- I
3 I
- I
pyridinecarbonitrile I
4a O
- O
r O
were O
prepared O
via O
either O
regioselective O
reaction O
of O
3 B
- I
aryl I
- I
1 I
- I
( I
1H I
- I
benzimidazol I
- I
2 I
- I
yl I
) I
- I
2 I
- I
propen I
- I
1 I
- I
ones I
3 O
with O
malononitrile B
or O
ylidenemalononitrile B
6 O
with O
2 B
- I
acetyl I
- I
1H I
- I
benzimidazoles I
1 O
in O

To O
explore O
the O
neurodevelopmental O
defects O
and O
the O
underlying O
mechanism O
associated O
with O
MeHg B
exposure O
, O
the O
cerebellum O
and O
cerebrum O
of O
Wistar O
rat O
pups O
were O
analyzed O
by O
[ B
( I
18 I
) I
F I
] I
FDG I
PET O
functional O
imaging O
, O
field O
potential O
analysis O
, O
and O
microarray O
gene O
expression O
profiling O
. O

The O
[ B
( I
18 I
) I
F I
] I
FDG I
PET O
imaging O
and O
field O
potential O
analysis O
suggested O
a O
delay O
in O
brain O
activity O
and O
impaired O
neural O
function O
by O
MeHg B
. O

In O
antioxidant O
assays O
all O
of O
the O
tested O
meroterpenes B
, O
and O
in O
particular O
cystodiones B
A I
( I
1 I
) I
and I
B I
( O
2 O
) O
, O
6 B
- I
cis I
- I
amentadione I
- I
1 I
' I
- I
methyl I
ether I
( O
7 O
) O
, O
and O
amentadione B
- I
1 I
' I
- I
methyl I
ether I
( O
8 O
) O
, O
exhibited O
strong O
radical O
- O
scavenging O
activity O
. O

In O
antioxidant O
assays O
all O
of O
the O
tested O
meroterpenes B
, O
and O
in O
particular O
cystodiones B
A I
( I
1 I
) I
and I
B I
( O
2 O
) O
, O
6 B
- I
cis I
- I
amentadione I
- I
1 I
' I
- I
methyl I
ether I
( O
7 O
) O
, O
and O
amentadione B
- I
1 I
' I
- I
methyl I
ether I
( O
8 O
) O
, O
exhibited O
strong O
radical O
- O
scavenging O
activity O
. O

In O
vivo O
binding O
of O
the O
dopamine B
- O
1 O
receptor O
PET O
tracers O
[ B
( I
11 I
) I
C I
] I
NNC112 I
and O
[ B
( I
11 I
) I
C I
] I
SCH23390 I
: O
a O
comparison O
study O
in O
individuals O
with O
schizophrenia O
. O

In O
vivo O
binding O
of O
the O
dopamine B
- O
1 O
receptor O
PET O
tracers O
[ B
( I
11 I
) I
C I
] I
NNC112 I
and O
[ B
( I
11 I
) I
C I
] I
SCH23390 I
: O
a O
comparison O
study O
in O
individuals O
with O
schizophrenia O
. O

OBJECTIVES O
: O
The O
aim O
of O
this O
investigation O
was O
to O
determine O
whether O
the O
in O
vivo O
characteristics O
of O
the O
different O
D1 O
receptor O
tracers O
used O
in O
previous O
reports O
, O
[ B
( I
11 I
) I
C I
] I
SCH23390 I
and O
[ B
( I
11 I
) I
C I
] I
NNC112 I
, O
may O
have O
contributed O
to O
these O
discrepancies O
reported O
in O
the O
literature O
. O

OBJECTIVES O
: O
The O
aim O
of O
this O
investigation O
was O
to O
determine O
whether O
the O
in O
vivo O
characteristics O
of O
the O
different O
D1 O
receptor O
tracers O
used O
in O
previous O
reports O
, O
[ B
( I
11 I
) I
C I
] I
SCH23390 I
and O
[ B
( I
11 I
) I
C I
] I
NNC112 I
, O
may O
have O
contributed O
to O
these O
discrepancies O
reported O
in O
the O
literature O
. O

METHODS O
: O
Eight O
patients O
with O
schizophrenia O
and O
12 O
healthy O
control O
subjects O
were O
scanned O
with O
both O
[ B
( I
11 I
) I
C I
] I
SCH23390 I
and O
[ B
( I
11 I
) I
C I
] I
NNC112 I
. O

METHODS O
: O
Eight O
patients O
with O
schizophrenia O
and O
12 O
healthy O
control O
subjects O
were O
scanned O
with O
both O
[ B
( I
11 I
) I
C I
] I
SCH23390 I
and O
[ B
( I
11 I
) I
C I
] I
NNC112 I
. O

RESULTS O
: O
[ B
( I
11 I
) I
C I
] I
SCH23390 I
and O
[ B
( I
11 I
) I
C I
] I
NNC112 I
binding O
potentials O
in O
both O
patients O
and O
control O
subjects O
were O
compared O
and O
no O
tracer O
by O
diagnosis O
interactions O
were O
observed O
. O

RESULTS O
: O
[ B
( I
11 I
) I
C I
] I
SCH23390 I
and O
[ B
( I
11 I
) I
C I
] I
NNC112 I
binding O
potentials O
in O
both O
patients O
and O
control O
subjects O
were O
compared O
and O
no O
tracer O
by O
diagnosis O
interactions O
were O
observed O
. O

CONCLUSIONS O
: O
The O
results O
of O
this O
study O
suggest O
that O
differences O
in O
the O
binding O
of O
[ B
( I
11 I
) I
C I
] I
SCH23390 I
and O
[ B
( I
11 I
) I
C I
] I
NNC112 I
observed O
in O
previous O
studies O
are O
not O
due O
to O
differences O
in O
the O
in O
vivo O
behavior O
of O
these O
tracers O
. O

CONCLUSIONS O
: O
The O
results O
of O
this O
study O
suggest O
that O
differences O
in O
the O
binding O
of O
[ B
( I
11 I
) I
C I
] I
SCH23390 I
and O
[ B
( I
11 I
) I
C I
] I
NNC112 I
observed O
in O
previous O
studies O
are O
not O
due O
to O
differences O
in O
the O
in O
vivo O
behavior O
of O
these O
tracers O
. O

Rhodamine B
B I
( O
Rh B
B I
) O
and O
fluorescein B
isothiocyanate I
( O
FITC B
) O
as O
model O
hydrophilic O
and O
hydrophobic O
small O
/ O
medium O
- O
size O
molecules O
, O
respectively O
, O
were O
encapsulated O
in O
poly B
lactic I
- I
co I
- I
glycolic I
acid I
( O
PLGA B
) O
nanoparticles O
( O
NPs O
) O
and O
delivered O
through O
full O
thickness O
porcine O
skin O
pretreated O
with O
MN O
array O
. O

Efficient O
synthesis O
and O
antimicrobial O
activity O
of O
some O
novel O
S B
- I
beta I
- I
d I
- I
glucosides I
of O
5 B
- I
aryl I
- I
1 I
, I
2 I
, I
4 I
- I
triazole I
- I
3 I
- I
thiones I
derivatives O
. O

A O
series O
of O
3 B
- I
S I
- I
beta I
- I
d I
- I
glucosides I
- I
4 I
- I
arylideneamino I
- I
5 I
- I
aryl I
- I
1 I
, I
2 I
, I
4 I
- I
triazoles I
were O
rationally O
designed O
and O
synthesized O
according O
to O
the O
principle O
of O
superposition O
of O
bioactive O
substructures O
by O
the O
combination O
of O
1 B
, I
2 I
, I
4 I
- I
triazole I
, O
Schiff B
base I
and O
glucosides B
. O

Here O
we O
synthesized O
a O
number O
of O
new O
derivatives O
of O
3 B
- I
methyl I
- I
benzyl I
- I
PP I
( O
3 B
- I
MB I
- I
PP I
, O
or O
1 O
) O
. O

Recent O
efforts O
to O
identify O
treatments O
for O
myocardial O
ischemia O
reperfusion O
injury O
have O
resulted O
in O
the O
discovery O
of O
a O
novel O
series O
of O
highly O
potent O
alpha B
, I
alpha I
- I
disubstituted I
amino I
acid I
- O
based O
arginase O
inhibitors O
. O

Synthesis O
of O
the O
target O
compounds O
was O
readily O
accomplished O
in O
good O
yields O
through O
a O
cyclisation O
reaction O
between O
indole B
- I
3 I
- I
carboxylic I
acid I
hydrazide I
and O
carbon B
disulfide I
under O
basic O
conditions O
, O
followed O
by O
S B
- O
benzylation O
. O

Herein O
, O
we O
develop O
a O
novel O
three O
- O
dimensional O
( O
3D O
) O
sulfur B
- I
nitrogen I
co I
- I
doped I
carbon I
foams O
( O
S B
- O
N B
- O
CF O
) O
with O
hierarchical O
pore O
structures O
, O
using O
a O
convenient O
, O
economical O
, O
and O
scalable O
method O
. O

The O
main O
proposed O
metabolic O
pathways O
in O
various O
in O
vitro O
systems O
were O
N B
- O
oxidation O
of O
the O
pyridine B
and O
/ O
or O
pyrimidine B
ring O
and O
conversion O
to O
4 B
- I
pyrimidone I
and O
pyrimidine B
- I
2 I
, I
4 I
- I
dione I
. O

We O
report O
a O
novel O
class O
of O
highly O
water O
- O
soluble O
decacationic B
methano I
[ I
60 I
] I
fullerene I
decaiodides I
C60 B
[ I
> I
M I
( I
C3N6 I
( I
+ I
) I
C3 I
) I
2 I
] I
- I
( I
I I
( I
- I
) I
) I
10 I
[ O
1 O
- O
( B
I I
( I
- I
) I
) I
10 I
] O
capable O
of O
co O
- O
producing O
singlet O
oxygen B
( O
Type O
- O
II O
) O
and O
highly O
reactive O
hydroxyl B
radicals O
, O
formed O
from O
superoxide B
radicals O
in O
Type O
- O
I O
photosensitizing O
reactions O
, O
upon O
illumination O
at O
both O
UVA O
and O
white O
light O
wavelengths O
. O

We O
report O
a O
novel O
class O
of O
highly O
water O
- O
soluble O
decacationic B
methano I
[ I
60 I
] I
fullerene I
decaiodides I
C60 B
[ I
> I
M I
( I
C3N6 I
( I
+ I
) I
C3 I
) I
2 I
] I
- I
( I
I I
( I
- I
) I
) I
10 I
[ O
1 O
- O
( B
I I
( I
- I
) I
) I
10 I
] O
capable O
of O
co O
- O
producing O
singlet O
oxygen B
( O
Type O
- O
II O
) O
and O
highly O
reactive O
hydroxyl B
radicals O
, O
formed O
from O
superoxide B
radicals O
in O
Type O
- O
I O
photosensitizing O
reactions O
, O
upon O
illumination O
at O
both O
UVA O
and O
white O
light O
wavelengths O
. O

The O
O2 B
( I
- I
) I
. I
- O
production O
efficiency O
of O
1 O
- O
( B
I I
( I
- I
) I
) I
10 I
was O
confirmed O
by O
using O
an O
O2 B
( I
- I
) I
. I
- O
reactive O
bis B
( I
2 I
, I
4 I
- I
dinitrobenzenesulfon I
) I
tetrafluorofluoresce I
probe O
and O
correlated O
to O
the O
photoinduced O
electron O
- O
transfer O
event O
going O
from O
iodide B
anions O
to O
( B
3 I
) I
C60 I
* I
[ I
> I
M I
( I
C3N6 I
( I
+ I
) I
C3 I
) I
2 I
] I
leading O
to O
C60 B
( I
- I
) I
. I
[ I
> I
M I
( I
C3N6 I
( I
+ I
) I
C3 I
) I
2 I
] I
. O

The O
cysteines B
required O
for O
desensitization O
are O
not O
accessible O
to O
all O
electrophiles O
as O
iodoacetamide B
and O
internally O
applied O
2 B
- I
( I
trimethylammonium I
) I
ethyl I
methanesulfonate I
failed O
to O
cause O
desensitization O
( O
despite O
large O
activation O
) O
. O

Furthermore O
, O
we O
examine O
the O
inhibitory O
effects O
of O
isopropyl B
- I
beta I
- I
d I
- I
thiogalactopyranosid I
( O
IPTG B
) O
on O
beta O
- O
galactosidase O
. O

[ B
( I
14 I
) I
C I
] I
Sorafenib I
( O
1 O
mu O
M O
) O
uptake O
at O
4 O
degrees O
C O
was O
~ O
61 O
- O
63 O
% O
of O
the O
uptake O
at O
37 O
degrees O
C O
, O
suggesting O
a O
high O
degree O
of O
passive O
diffusion O
. O

Hepatocyte O
uptake O
of O
[ B
( I
14 I
) I
C I
] I
sorafenib I
was O
not O
Na B
( I
+ I
) I
- O
dependent O
or O
influenced O
by O
the O
organic O
anion O
transporter O
2 O
( O
OAT2 O
) O
inhibitor O
ketoprofen B
. O

However O
, O
initial O
[ B
( I
14 I
) I
C I
] I
sorafenib I
hepatocyte O
uptake O
was O
reduced O
by O
46 O
and O
30 O
% O
compared O
to O
control O
values O
in O
the O
presence O
of O
the O
organic O
anion O
transporting O
polypeptide O
( O
OATP O
) O
inhibitor O
rifamycin B
SV I
, O
and O
the O
organic O
cation O
transporter O
( O
OCT O
) O
inhibitor O
decynium B
22 I
, O
respectively O
. O

[ B
( I
14 I
) I
C I
] I
Sorafenib I
( O
0 O
. O
5 O
to O
5 O
mu O
M O
) O
uptake O
was O
significantly O
higher O
in O
hOCT1 O
- O
transfected O
CHO O
cells O
compared O
to O
mock O
cells O
, O
and O
inhibited O
by O
the O
general O
OCT O
inhibitor O
, O
MPP B
( I
+ I
) I
. O

In O
TF B
3 I
' I
- I
O I
- I
gallate I
- O
pretreated O
cells O
, O
Western O
blot O
analysis O
revealed O
attenuated O
expression O
of O
PEPT1 O
transporter O
and O
Gly B
- I
Sar I
transport O
was O
completely O
ameliorated O
by O
10 O
mu O
M O
Compound B
C I
, O
an O
AMP B
- O
activated O
protein O
kinase O
( O
AMPK O
) O
inhibitor O
. O

Further O
, O
we O
demonstrated O
that O
2 B
- I
hydroxy I
- I
3 I
- I
pentanone I
and O
1 B
- I
hydroxy I
- I
2 I
- I
propanone I
, O
thermal O
degradation O
products O
of O
monosaccharides B
, O
were O
closely O
related O
to O
the O
formation O
of O
cis B
- I
2 I
, I
6 I
- I
dimethyl I
- I
1 I
, I
4 I
- I
cyclohexanedione I
. O

Further O
, O
we O
demonstrated O
that O
2 B
- I
hydroxy I
- I
3 I
- I
pentanone I
and O
1 B
- I
hydroxy I
- I
2 I
- I
propanone I
, O
thermal O
degradation O
products O
of O
monosaccharides B
, O
were O
closely O
related O
to O
the O
formation O
of O
cis B
- I
2 I
, I
6 I
- I
dimethyl I
- I
1 I
, I
4 I
- I
cyclohexanedione I
. O

We O
developed O
a O
new O
synthetic O
approach O
to O
high O
molecular O
weight O
poly B
( I
p I
- I
phenylenebutadiynyle I
) I
s I
( O
PPBs B
) O
by O
increasing O
backbone O
flexibility O
. O

The O
relative O
potencies O
of O
these O
piperidine B
alkaloids I
on O
cells O
expressing O
human O
fetal O
muscle O
- O
type O
nicotinic O
acetylcholine B
receptors O
had O
the O
rank O
order O
of O
gamma B
- I
coniceine I
> O
( B
- I
) I
- I
N I
- I
methylconiine I
> O
( B
+ I
/ I
- I
) I
- I
N I
- I
methylconiine I
> O
( B
+ I
) I
- I
N I
- I
methylconiine I
. O

The O
relative O
potencies O
of O
these O
piperidine B
alkaloids I
on O
cells O
expressing O
human O
fetal O
muscle O
- O
type O
nicotinic O
acetylcholine B
receptors O
had O
the O
rank O
order O
of O
gamma B
- I
coniceine I
> O
( B
- I
) I
- I
N I
- I
methylconiine I
> O
( B
+ I
/ I
- I
) I
- I
N I
- I
methylconiine I
> O
( B
+ I
) I
- I
N I
- I
methylconiine I
. O

Finally O
, O
pretreatment O
with O
the O
antioxidant O
N B
- I
acetyl I
- I
L I
- I
cysteine I
( O
NAC B
) O
reduced O
the O
OTA B
- O
induced O
DNA O
DSBs O
, O
ATM O
phosphorylation O
, O
and O
G2 O
arrest O
. O

Poly B
- I
lactide I
- I
co I
- I
glycolide I
( O
PLGA B
) O
microparticles O
emerged O
as O
one O
of O
the O
most O
promising O
strategies O
to O
achieve O
site O
- O
specific O
drug O
delivery O
. O

We O
created O
hydrolytically O
degradable O
hydrogel O
/ O
bioceramic O
biocomposites O
, O
comprising O
poly B
( I
2 I
- I
hydroxyethyl I
methacrylate I
) I
( O
pHEMA B
) O
hydrogels O
and O
50 O
wt O
% O
biphasic O
hydroxyapatite B
/ O
beta B
- I
tricalcium I
phosphate I
( O
60 O
/ O
40 O
) O
through O
in O
situ O
polymerization O
. O

The O
data O
described O
in O
the O
present O
article O
are O
in O
complete O
agreement O
with O
this O
proposition O
as O
they O
show O
that O
it O
was O
possible O
to O
trap O
these O
thiolactone B
sulfoxides I
by O
a O
series O
of O
nucleophiles O
such O
as O
amines B
, O
thiols B
, O
or O
cyclopentane B
- I
1 I
, I
3 I
- I
dione I
( O
CPDH B
) O
, O
an O
equivalent O
of O
dimedone B
that O
is O
used O
as O
a O
sulfenic B
acid I
trapping O
agent O
. O

Synthesis O
and O
in O
Vitro O
Characterisation O
of O
Ifenprodil B
- O
Based O
Fluorescein B
Conjugates O
as O
GluN1 O
/ O
GluN2B O
N B
- I
Methyl I
- I
D I
- I
aspartate I
Receptor O
Antagonists O
. O

Despite O
effects O
of O
lesser O
amplitude O
with O
these O
probes O
relative O
to O
ifenprodil B
, O
we O
demonstrated O
that O
they O
displaced O
[ B
( I
3 I
) I
H I
] I
ifenprodil I
in O
mouse O
brain O
slices O
in O
a O
similar O
manner O
. O

Kinetic O
analysis O
of O
the O
rates O
of O
metabolite O
formation O
revealed O
that O
the O
major O
metabolites O
were O
5 B
- I
hydroxy I
- I
2 I
, I
2 I
' I
, I
4 I
, I
4 I
' I
- I
tetrabromodiphenyl I
ether I
( O
5 B
- I
OH I
- I
BDE I
- I
47 I
) O
, O
6 B
- I
hydroxy I
- I
2 I
, I
2 I
' I
, I
4 I
, I
4 I
' I
- I
tetrabromodiphenyl I
ether I
( O
6 B
- I
OH I
- I
BDE I
- I
47 I
) O
, O
and O
possibly O
the O
unidentified O
monohydroxy B
- O
tetrabrominated O
metabolite O
. O

Kinetic O
analysis O
of O
the O
rates O
of O
metabolite O
formation O
revealed O
that O
the O
major O
metabolites O
were O
5 B
- I
hydroxy I
- I
2 I
, I
2 I
' I
, I
4 I
, I
4 I
' I
- I
tetrabromodiphenyl I
ether I
( O
5 B
- I
OH I
- I
BDE I
- I
47 I
) O
, O
6 B
- I
hydroxy I
- I
2 I
, I
2 I
' I
, I
4 I
, I
4 I
' I
- I
tetrabromodiphenyl I
ether I
( O
6 B
- I
OH I
- I
BDE I
- I
47 I
) O
, O
and O
possibly O
the O
unidentified O
monohydroxy B
- O
tetrabrominated O
metabolite O
. O

For O
two O
of O
them O
, O
viz O
. O
, O
3 B
' I
, I
4 I
' I
- I
dimethoxywogonin I
and O
4 B
' I
- I
hydroxywogonin I
, O
such O
data O
have O
not O
been O
reported O
in O
literature O
. O

Two O
new O
tryptophan B
derivatives O
, O
N B
- I
sulfonyl I
- I
L I
- I
tryptophan I
( O
tryptorheedei B
A I
) O
( O
1 O
) O
and O
3 B
- I
( I
N I
- I
sulfonylindolyl I
) I
- I
D I
- I
lactic I
acid I
( O
tryptorheedei B
B I
) O
( O
2 O
) O
together O
with O
the O
known O
5 B
- I
O I
- I
beta I
- I
D I
- I
glucopyranosyl I
- I
2 I
- I
hydroxyphenylacetic I
acid I
( O
3 O
) O
, O
1 B
- I
O I
- I
methylglucopyranosid I
, O
entadamide B
A I
, O
homogentisic B
acid I
and O
3 B
- I
O I

The O
reported O
compounds O
herein O
are O
: O
4 B
- I
aminothienopyrimidin I
derivatives O
4a O
, O
b O
and O
their O
4 B
- I
substituted I
phenylamino I
analogues O
8a O
, O
b O
; O
4 B
- I
thienopyrimidin I
- I
4 I
- I
ones I
5a O
, O
b O
; O
N B
- I
alkyl I
thienopyrimidin I
- I
4 I
- I
ones I
6a O
- O
g O
; O
4 B
- I
chlorothienopyrimidi I
7a O
, O
b O
; O
and O
thienopyrimidoquinaz B
9a O
, O
b O
which O
are O
the O
structural O
mimics O
of O
8a O
, O
b O
. O

The O
fine O
particulate O
( O
PM O
< O
2 O
. O
5 O
mu O
m O
) O
of O
wood O
smoke O
were O
the O
most O
potent O
TRPA1 O
agonists O
and O
several O
chemical O
constituents O
of O
wood O
smoke O
particulate O
, O
3 B
, I
5 I
- I
ditert I
- I
butylphenol I
, O
coniferaldehyde B
, O
formaldehyde B
, O
perinaphthenone B
, O
agathic B
acid I
, O
and O
isocupressic B
acid I
, O
were O
TRPA1 O
agonists O
. O

TRPA1 O
activation O
by O
wood O
smoke O
particles O
occurred O
through O
the O
electrophile O
/ O
oxidant O
- O
sensing O
domain O
( O
i O
. O
e O
. O
, O
C621 O
/ O
C641 O
/ O
C665 O
/ O
K710 O
) O
, O
based O
on O
the O
inhibition O
of O
cellular O
responses O
when O
the O
particles O
were O
pretreated O
with O
glutathione B
; O
a O
role O
for O
the O
menthol B
- O
binding O
site O
of O
TRPA1 O
( O
S873 O
/ O
T874 O
) O
was O
demonstrated O
for O
3 B
, I
5 I
- I
ditert I
- I
butylphenol I
. O

Mancozeb B
( O
manganese B
/ I
zinc I
ethylene I
bis I
- I
dithiocarbamate I
) O
is O
an O
organometallic O
fungicide O
that O
has O
been O
associated O
with O
human O
neurotoxicity O
and O
neurodegeneration O
. O

Memory O
impairment O
was O
induced O
by O
scopolamine B
, O
a O
muscarinic O
receptor O
antagonist O
, O
or O
MK B
- I
801 I
, O
an O
N B
- I
methyl I
- I
D I
- I
aspartate I
receptor O
antagonist O
. O

A O
series O
of O
six O
/ O
five O
member O
( B
E I
/ I
Z I
) I
- I
Goniothalamin I
analogs O
were O
synthesized O
from O
commercially O
available O
( B
3 I
, I
4 I
- I
dihydro I
- I
2H I
- I
pyran I
- I
2 I
- I
yl I
) I
methanol I
/ O
5 B
- I
( I
hydroxymethyl I
) I
dihydrofuran I
- I
2 I
( I
3H I
) I
- I
one I
in O
three O
steps O
with O
good O
to O
moderate O
overall O
yields O
and O
their O
cytotoxicity O
against O
lymphoblastic O
leukemic O
T O
cell O
line O
( O
Jurkat O
E6 O
. O
1 O
) O
have O
been O
evaluated O
. O

Enzymatically O
catalyzed O
polycondensation O
of O
p B
- I
xylylenediamine I
and O
diethyl B
sebacate I
resulted O
in O
oligo B
( I
p I
- I
xylylene I
sebacamide I
) I
with O
high O
melting O
temperatures O
( O
223 O
- O
230 O
degrees O
C O
) O
and O
the O
enzymatic O
polycondensation O
of O
dimethyl B
terephthalate I
and O
1 B
, I
8 I
- I
diaminooctane I
leads O
to O
oligo B
( I
octamethylene I
terephthalamide I
) I
with O
two O
melting O
temperatures O
at O
186 O
and O
218 O
degrees O
C O
. O

The O
highest O
DPmax O
of O
15 O
was O
achieved O
in O
a O
one O
- O
step O
and O
two O
- O
step O
synthesis O
of O
oligo B
( I
p I
- I
xylylene I
sebacamide I
) I
catalyzed O
by O
CLEA O
cutinase O
. O

The O
reaction O
tolerates O
a O
broad O
range O
of O
benzhydroxamic B
acids I
and O
diazo B
compounds O
, O
including O
substituted O
2 B
, I
2 I
, I
2 I
- I
trifluorodiazoethane I
. O

2 O
. O
In O
this O
two O
- O
part O
study O
, O
we O
investigated O
the O
metabolism O
, O
disposition O
of O
[ B
( I
14 I
) I
C I
] I
pazopanib I
, O
and O
the O
oral O
bioavailability O
of O
pazopanib B
tablets O
in O
patients O
with O
advanced O
cancer O
. O

3 O
. O
In O
part O
A O
, O
three O
men O
each O
received O
a O
single O
oral O
dose O
of O
[ B
( I
14 I
) I
C I
] I
pazopanib I
in O
suspension O
( O
400 O
mg O
, O
70 O
micro O
Ci O
) O
. O

2 B
- I
Hydroxy I
- I
3 I
- I
methylanthraquinone I
from O
Hedyotis O
diffusa O
Willd O
induces O
apoptosis O
in O
human O
leukemic O
U937 O
cells O
through O
modulation O
of O
MAPK O
pathways O
. O

The O
current O
study O
determines O
the O
role O
of O
mitogen O
- O
activated O
protein O
kinases O
( O
MAPK O
) O
in O
human O
leukemic O
U937 O
cells O
apoptosis O
induced O
by O
2 B
- I
hydroxy I
- I
3 I
- I
methylanthraquinone I
from O
H O
. O
diffusa O
. O

Our O
results O
showed O
that O
2 B
- I
hydroxy I
- I
3 I
- I
methylanthraquinone I
decreased O
phosphorylation O
- O
ERK1 O
/ O
2 O
( O
p O
- O
ERK1 O
/ O
2 O
) O
, O
and O
increased O
p O
- O
p38MAPK O
, O
but O
did O
not O
affect O
expressions O
of O
p O
- O
JNK1 O
/ O
2 O
in O
U937 O
cells O
. O

Moreover O
, O
treatment O
of O
U937 O
cells O
with O
2 B
- I
hydroxy I
- I
3 I
- I
methylanthraquinone I
resulted O
in O
activation O
of O
caspase O
- O
3 O
. O

Furthermore O
, O
PD98059 B
( O
ERK1 O
/ O
2 O
inhibitor O
) O
significantly O
enhanced O
2 B
- I
hydroxy I
- I
3 I
- I
methylanthraquinone I
- O
induced O
apoptosis O
in O
U937 O
cells O
, O
whereas O
caspase O
- O
3 O
inhibitor O
or O
SB203580 B
( O
p O
- O
p38MAPK O
inhibitor O
) O
, O
decreased O
apoptosis O
in O
U937 O
cells O
. O

Taken O
together O
, O
our O
study O
for O
the O
first O
time O
suggests O
that O
2 B
- I
hydroxy I
- I
3 I
- I
methylanthraquinone I
is O
able O
to O
enhance O
apoptosis O
of O
U937 O
cells O
, O
at O
least O
in O
part O
, O
through O
activation O
of O
p O
- O
p38MAPK O
and O
downregulation O
of O
p O
- O
ERK1 O
/ O
2 O
. O

A O
high O
throughput O
assay O
for O
the O
glucuronidation O
of O
7 B
- I
hydroxy I
- I
4 I
- I
trifluoromethylcouma I
by O
recombinant O
human O
UDP B
- O
glucuronosyltransfer O
and O
liver O
microsomes O
. O

2 O
. O
We O
have O
developed O
a O
convenient O
quantitative O
multi O
- O
well O
plate O
assay O
to O
measure O
the O
glucuronidation O
rate O
of O
7 B
- I
hydroxy I
- I
4 I
- I
trifluoromethylcouma I
( O
HFC B
) O
for O
several O
UGTs O
. O

Metabolites O
of O
norepinephrine B
[ O
3 B
- I
methoxy I
- I
4 I
- I
hydroxyphenylglycol I
( O
MHPG B
) O
and O
vanillylmandelic B
acid I
( O
VMA B
) O
] O
and O
dopamine B
[ O
homovanillic B
acid I
( O
HVA B
) O
] O
were O
measured O
by O
high O
- O
pressure O
liquid O
chromatography O
with O
electrochemical O
detection O
. O

A O
new O
molecularly O
imprinted O
polymer O
( O
MIP O
) O
, O
selective O
for O
major O
metabolites O
of O
quinoxaline B
- I
1 I
, I
4 I
- I
dioxides I
, O
was O
prepared O
through O
bulk O
polymerisation O
using O
quinoxaline B
- I
2 I
- I
carboxylic I
acid I
( O
QCA B
) O
as O
template O
, O
diethylaminoethylmet B
as O
functional O
monomer O
and O
ethylene B
glycol I
dimethacrylate I
as O
cross O
- O
linker O
in O
tetrahydrofuran B
. O

Various O
ursanic B
, I
oleanic I
and I
lupanic I
pentacyclic I
triterpenoids I
found O
in O
apple O
peel O
were O
studied O
for O
anti O
- O
inflammatory O
effects O
in O
vitro O
using O
T84 O
colon O
carcinoma O
cells O
. O

The O
12 O
flavonoids B
identified O
were O
quercetin B
3 I
- I
O I
- I
robinobioside I
, O
quercetin B
3 I
- I
O I
- I
rutinoside I
, O
quercetin B
3 I
' I
- I
O I
- I
galactoside I
, O
quercetin B
3 I
' I
- I
O I
- I
glucoside I
, O
quercetin B
3 I
' I
- I
O I
- I
rhamnoside I
, O
quercetin B
3 I
' I
- I
O I
- I
pentosylhexoside I
, O
quercetin B
3 I
- I
O I
- I
6 I
' I
malonylglucoside I
, O
quercetin B
3 I
' I
- I
O I
- I

The O
12 O
flavonoids B
identified O
were O
quercetin B
3 I
- I
O I
- I
robinobioside I
, O
quercetin B
3 I
- I
O I
- I
rutinoside I
, O
quercetin B
3 I
' I
- I
O I
- I
galactoside I
, O
quercetin B
3 I
' I
- I
O I
- I
glucoside I
, O
quercetin B
3 I
' I
- I
O I
- I
rhamnoside I
, O
quercetin B
3 I
' I
- I
O I
- I
pentosylhexoside I
, O
quercetin B
3 I
- I
O I
- I
6 I
' I
malonylglucoside I
, O
quercetin B
3 I
' I
- I
O I
- I

The O
12 O
flavonoids B
identified O
were O
quercetin B
3 I
- I
O I
- I
robinobioside I
, O
quercetin B
3 I
- I
O I
- I
rutinoside I
, O
quercetin B
3 I
' I
- I
O I
- I
galactoside I
, O
quercetin B
3 I
' I
- I
O I
- I
glucoside I
, O
quercetin B
3 I
' I
- I
O I
- I
rhamnoside I
, O
quercetin B
3 I
' I
- I
O I
- I
pentosylhexoside I
, O
quercetin B
3 I
- I
O I
- I
6 I
' I
malonylglucoside I
, O
quercetin B
3 I
' I
- I
O I
- I

The O
12 O
flavonoids B
identified O
were O
quercetin B
3 I
- I
O I
- I
robinobioside I
, O
quercetin B
3 I
- I
O I
- I
rutinoside I
, O
quercetin B
3 I
' I
- I
O I
- I
galactoside I
, O
quercetin B
3 I
' I
- I
O I
- I
glucoside I
, O
quercetin B
3 I
' I
- I
O I
- I
rhamnoside I
, O
quercetin B
3 I
' I
- I
O I
- I
pentosylhexoside I
, O
quercetin B
3 I
- I
O I
- I
6 I
' I
malonylglucoside I
, O
quercetin B
3 I
' I
- I
O I
- I

Nine O
phenolic B
acids I
, O
protocatechuic B
acid I
, O
p B
- I
hydroxybenzoic I
acid I
, O
ferulic B
acid I
, O
chlorogenic B
acid I
, O
vanillic B
acid I
, O
caffeic B
acid I
, O
vanillin B
, O
ortho B
- I
and I
para I
- I
coumaric I
acids I
, O
were O
identified O
and O
quantified O
. O

While O
three O
flavonoids B
, O
quercetin B
- I
3 I
- I
O I
- I
sambubioside I
, O
rutin B
and O
isoquercitrin B
were O
purified O
by O
petroleum B
ether I
- O
ethyl B
acetate I
- O
methanol B
- O
water O
( O
1 O
: O
5 O
: O
1 O
: O
5 O
, O
v O
/ O
v O
/ O
v O
/ O
v O
) O
. O

In O
addition O
, O
an O
intermediary O
monomer O
, O
bis B
( I
2 I
- I
hydroxyethyl I
) I
terephthalate I
, O
was O
found O
but O
only O
in O
PET B
- O
bottled O
waters O
. O

This O
innovation O
has O
allowed O
the O
discovery O
that O
, O
in O
addition O
to O
13 B
( I
2 I
) I
OH I
chl I
a I
and O
15 B
( I
1 I
) I
OH I
lactone I
chl I
a I
, O
which O
are O
the O
first O
products O
of O
POD O
on O
chl B
a I
, O
the O
reaction O
process O
sequentially O
creates O
another O
series O
of O
oxidised O
chlorophyll B
derivatives O
which O
have O
not O
been O
previously O
described O
. O

Of O
the O
WPH O
components O
tested O
, O
the O
amino O
acid O
l B
- I
isoleucine I
and O
the O
peptide O
l B
- I
leucyl I
- I
l I
- I
isoleucine I
showed O
greater O
efficiency O
in O
translocating O
GLUT O
- O
4 O
to O
the O
PM O
and O
of O
increasing O
glucose B
capture O
by O
skeletal O
muscle O
. O

In O
in O
vitro O
antioxidant O
study O
, O
the O
free O
radical O
scavenging O
effect O
of O
friedelin B
on O
2 B
, I
2 I
- I
diphenyl I
- I
picrylhydrazyl I
( O
DPPH B
) O
, O
hydroxyl B
, O
nitric B
oxide I
and O
superoxide B
radicals O
were O
evaluated O
. O

The O
results O
showed O
that O
WFI O
inhibited O
the O
mutagenicity O
of O
2 B
- I
aminoanthracene I
( O
2 B
- I
AA I
) O
, O
an O
indirect O
mutagen O
; O
and O
4 B
- I
nitroquinoline I
- I
N I
- I
oxide I
( O
4 B
- I
NQO I
) O
, O
a O
direct O
mutagen O
toward O
Salmonella O
typhimurium O
TA O
98 O
and O
TA O
100 O
. O

In O
addition O
, O
AHS O
significantly O
increased O
the O
expression O
of O
plasticity O
- O
related O
proteins O
including O
postsynaptic O
density O
- O
95 O
, O
phosphor O
- O
N B
- I
methyl I
- I
d I
- I
aspartate I
receptor O
1 O
, O
phospho B
- O
calcium B
- O
calmodulin O
dependent O
kinase O
II O
, O
phospho B
- O
protein O
kinase O
A O
Catalytic O
beta O
subunit O
, O
protein O
kinase O
C O
gamma O
subunit O
, O
phospho B
- O
CREB O
and O
brain O
derived O
neurotrophic O
factor O
. O

The O
main O
components O
found O
by O
LC O
- O
MS O
analysis O
were O
quercetin B
- I
3 I
- I
O I
- I
( I
2 I
- I
rhamnosyl I
) I
rutinoside I
, O
kaempferol B
- I
3 I
- I
O I
- I
( I
2 I
- I
rhamnosyl I
) I
rutinoside I
, O
quercetin B
- I
3 I
- I
O I
- I
rutinoside I
and O
kaempferol B
- I
3 I
- I
O I
- I
rutinoside I
. O

The O
main O
components O
found O
by O
LC O
- O
MS O
analysis O
were O
quercetin B
- I
3 I
- I
O I
- I
( I
2 I
- I
rhamnosyl I
) I
rutinoside I
, O
kaempferol B
- I
3 I
- I
O I
- I
( I
2 I
- I
rhamnosyl I
) I
rutinoside I
, O
quercetin B
- I
3 I
- I
O I
- I
rutinoside I
and O
kaempferol B
- I
3 I
- I
O I
- I
rutinoside I
. O

Rotenone B
treatment O
also O
resulted O
in O
reduction O
of O
[ B
( I
3 I
) I
H I
] I
dopamine I
uptake O
and O
mitochondrial O
complex O
I O
activity O
in O
the O
striatum O
of O
rats O
with O
neonatal O
LPS O
exposure O
, O
but O
not O
in O
those O
without O
this O
exposure O
. O

Analysis O
of O
the O
antioxidant O
properties O
of O
differently O
substituted O
2 B
- I
and I
3 I
- I
indolyl I
carbohydrazides I
and O
related O
derivatives O
. O

Adenine B
- O
DNA O
Adducts O
Derived O
from O
the O
Highly O
Tumorigenic O
Dibenzo B
[ I
a I
, I
l I
] I
pyrene I
Are O
Resistant O
to O
Nucleotide B
Excision O
Repair O
while O
Guanine B
Adducts O
Are O
Not O
. O

Here O
we O
compared O
, O
in O
the O
same O
sequence O
context O
, O
the O
relative O
NER O
dual O
incision O
efficiencies O
elicited O
by O
two O
stereochemically O
distinct O
pairs O
of O
guanine B
( O
N O
( O
2 O
) O
- O
dG O
) O
and O
adenine B
( O
N O
( O
6 O
) O
- O
dA O
) O
DNA O
lesions O
, O
derived O
from O
enantiomeric O
genotoxic O
diol B
epoxides I
of O
the O
highly O
tumorigenic O
fjord O
region O
polycyclic O
aromatic O
hydrocarbon O
dibenzo B
[ I
a I
, I
l I
] I
pyrene I
( O
DB B
[ I
a I
, I
l I
] I
P I
) O
. O

Here O
we O
compared O
, O
in O
the O
same O
sequence O
context O
, O
the O
relative O
NER O
dual O
incision O
efficiencies O
elicited O
by O
two O
stereochemically O
distinct O
pairs O
of O
guanine B
( O
N O
( O
2 O
) O
- O
dG O
) O
and O
adenine B
( O
N O
( O
6 O
) O
- O
dA O
) O
DNA O
lesions O
, O
derived O
from O
enantiomeric O
genotoxic O
diol B
epoxides I
of O
the O
highly O
tumorigenic O
fjord O
region O
polycyclic O
aromatic O
hydrocarbon O
dibenzo B
[ I
a I
, I
l I
] I
pyrene I
( O
DB B
[ I
a I
, I
l I
] I
P I
) O
. O

Our O
results O
are O
consistent O
with O
the O
hypothesis O
that O
the O
high O
genotoxic O
activity O
of O
DB B
[ I
a I
, I
l I
] I
P I
is O
related O
to O
the O
formation O
of O
NER O
- O
resistant O
and O
persistent O
DB B
[ I
a I
, I
l I
] I
P I
- O
derived O
adenine B
adducts O
in O
cellular O
DNA O
. O

Our O
results O
are O
consistent O
with O
the O
hypothesis O
that O
the O
high O
genotoxic O
activity O
of O
DB B
[ I
a I
, I
l I
] I
P I
is O
related O
to O
the O
formation O
of O
NER O
- O
resistant O
and O
persistent O
DB B
[ I
a I
, I
l I
] I
P I
- O
derived O
adenine B
adducts O
in O
cellular O
DNA O
. O

This O
expands O
the O
number O
of O
known O
solvents O
which O
can O
support O
amphiphilic O
self O
- O
assembly O
to O
ethanol B
, O
acetone B
, O
tetrahydrofuran B
, O
N B
- I
dimethylformamide I
, O
N B
- I
cyclohexyl I
- I
2 I
- I
pyrrolidone I
, O
and O
a O
number O
of O
other O
organic O
solvents O
, O
many O
of O
which O
were O
not O
known O
to O
afford O
solvophobic O
self O
- O
assembly O
prior O
to O
this O
report O
. O

The O
development O
of O
t B
- I
2 I
- I
heptenal I
and O
1 B
- I
octen I
- I
3 I
- I
ol I
increased O
greatly O
in O
chlorophyll B
sensitised O
O O
/ O
W O
emulsions O
with O
an O
increase O
in O
beta B
- I
carotene I
concentration O
, O
implying O
that O
more O
singlet O
oxygen B
oxidation O
occurred O
due O
to O
the O
higher O
levels O
of O
remaining O
chlorophylls B
. O

However O
, O
the O
content O
of O
t B
- I
2 I
- I
heptenal I
and O
1 B
- I
octen I
- I
3 I
- I
ol I
in O
the O
riboflavin B
sensitised O
O O
/ O
W O
emulsions O
was O
not O
significantly O
correlated O
with O
the O
beta B
- I
carotene I
concentration O
, O
which O
indicates O
that O
beta B
- I
carotene I
in O
the O
lipid O
particles O
effectively O
quenched O
singlet O
oxygen B
. O

Synthesis O
and O
antitumor O
activity O
of O
1 B
, I
3 I
, I
4 I
- I
oxadiazole I
possessing O
1 B
, I
4 I
- I
benzodioxan I
moiety O
as O
a O
novel O
class O
of O
potent O
methionine B
aminopeptidase O
type O
II O
inhibitors O
. O

A O
series O
of O
1 B
, I
3 I
, I
4 I
- I
oxadiazole I
derivatives O
containing O
1 B
, I
4 I
- I
benzodioxan I
moiety O
( O
7a O
- O
7q O
) O
have O
been O
designed O
, O
synthesized O
and O
evaluated O
for O
their O
antitumor O
activity O
. O

Two O
new O
sesqui B
- I
neolignans I
with O
novel O
conjugation O
way O
, O
simonol B
A I
( O
1 O
) O
, O
featuring O
a O
unique O
motif O
of O
a O
5 B
, I
5 I
- I
dihydro I
- I
pyran I
with O
a O
hemiketal B
carbon I
, O
while O
simonol B
B I
( O
2 O
) O
possessing O
two O
dihydronfuran B
rings O
in O
the O
same O
direction O
, O
were O
isolated O
from O
the O
ethanol B
extract O
of O
the O
fruits O
of O
Illicium O
simonii O
. O

Related O
homogeneous O
ligand O
L B
( I
t I
) I
( I
Bu I
) I
and O
its O
Ni B
( I
II I
) I
complexes O
, O
[ B
Ni I
( I
L I
( I
t I
) I
( I
Bu I
) I
) I
( I
OAc I
) I
2 I
( I
H2 I
O I
) I
] I
( I
L I
( I
t I
) I
( I
Bu I
) I
/ I
Ni I
) I
and O
[ B
Ni I
( I
L I
( I
t I
) I
( I
Bu I
) I
) I
2 I
] I
BF4 I
( I
2 I
L I
( I
t I
) I
( I
Bu I
) I
/ I
Ni I
) I
, O
have O
been O
synthesized O
. O

The O
catalyst O
with O
the O
lowest O
loading O
shows O
high O
activity O
in O
its O
initial O
use O
as O
the O
homogeneous O
L B
( I
t I
) I
( I
Bu I
) I
/ O
Ni B
catalyst O
, O
with O
some O
metal O
leaching O
. O

We O
have O
demonstrated O
that O
the O
complementary O
combination O
of O
grazing O
incidence O
X O
- O
ray O
fluorescence O
( O
GIXF O
) O
with O
specular O
X O
- O
ray O
reflectivity O
( O
XRR O
) O
can O
be O
used O
to O
quantitatively O
determine O
the O
density O
profiles O
of O
Ni B
( I
2 I
) I
( I
+ I
) I
ions O
complexed O
with O
chelator O
headgroups O
as O
well O
as O
S B
atoms O
in O
recombinant O
proteins O
anchored O
to O
lipid O
monolayers O
at O
the O
air O
/ O
water O
interface O
. O

The O
fine O
- O
structures O
perpendicular O
to O
the O
global O
plane O
of O
monolayers O
were O
characterized O
by O
XRR O
in O
the O
presence O
of O
Ni B
( I
2 I
) I
( I
+ I
) I
ions O
, O
yielding O
the O
thickness O
, O
roughness O
, O
and O
electron O
density O
of O
the O
stratified O
lipid O
monolayers O
. O

X O
- O
ray O
fluorescence O
intensities O
from O
Ni B
K O
alpha O
core O
levels O
recorded O
at O
the O
incidence O
angles O
below O
and O
above O
the O
critical O
angle O
of O
total O
reflection O
allow O
for O
the O
determination O
of O
the O
position O
and O
lateral O
density O
of O
Ni B
( I
2 I
) I
( I
+ I
) I
ions O
associated O
with O
chelator O
headgroups O
with O
a O
high O
spatial O
accuracy O
( O
+ O
/ O
- O
5 O
A O
) O
. O

The O
challenge O
of O
locating O
two O
d B
- I
and I
one I
l I
- I
valine I
residue O
in O
1 O
and O
2 O
was O
accomplished O
by O
total O
synthesis O
using O
solid O
- O
phase O
peptide O
synthetic O
methods O
. O

Here O
, O
we O
investigate O
the O
self O
- O
assembly O
of O
these O
superstructures O
by O
comparing O
the O
quiescent O
and O
vortex O
- O
assisted O
aggregation O
of O
insulin O
and O
its O
individual O
A O
and O
B O
chains O
in O
the O
presence O
or O
absence O
of O
reducing O
agent O
tris B
( I
2 I
- I
carboxyethyl I
) I
phosphine I
( O
TCEP B
) O
. O

We O
have O
investigated O
the O
effect O
of O
melatonin B
and O
its O
analogue O
5 B
- I
methoxycarbonylamino I
- I
N I
- I
acetyltryptamine I
, O
5 B
- I
MCA I
- I
NAT I
, O
on O
beta O
2 O
/ O
alpha O
2A O
- O
adrenergic O
receptor O
mRNA O
as O
well O
as O
protein O
expression O
in O
cultured O
rabbit O
non O
- O
pigmented O
ciliary O
epithelial O
cells O
. O

Fructose B
- I
1 I
, I
6 I
- I
bisphosphate I
ameliorates O
lipopolysaccharide O
- O
induced O
dysfunction O
of O
blood O
- O
brain O
barrier O
. O

Fructose B
- I
1 I
, I
6 I
- I
bisphosphate I
( O
FBP B
) O
, O
a O
glycolytic O
intermediate O
, O
has O
neuroprotective O
effects O
in O
various O
brain O
injury O
models O
. O

The O
first O
total O
synthesis O
of O
viequeamide B
A I
, O
a O
natural O
cyclic O
depsipeptide O
isolated O
from O
a O
marine O
button O
cyanobacterium O
, O
was O
achieved O
with O
the O
N B
- I
Me I
- I
Val I
- I
Thr I
peptide O
bond O
as O
the O
final O
macrocyclization O
site O
. O

The O
poly B
( I
benzyl I
1 I
, I
2 I
- I
glycerol I
carbonate I
) I
s I
were O
obtained O
via O
the O
ring O
- O
opening O
copolymerization O
of O
rac B
- I
/ I
( I
R I
) I
- I
benzyl I
glycidyl I
ether I
with O
CO2 B
using O
[ B
SalcyCo I
( I
III I
) I
X I
] I
complexes O
with O
high O
carbonate B
linkage O
selectivity O
and O
polymer O
/ O
cyclic O
carbonate B
selectivity O
( O
> O
99 O
% O
) O
. O

A O
new O
ent B
- I
kaurane I
diterpenoid B
glycoside I
( O
1 O
) O
, O
named O
glaucocalyxin B
G I
, O
has O
been O
isolated O
from O
the O
n B
- I
butanol I
- O
soluble O
fraction O
of O
the O
dried O
whole O
plants O
of O
Isodon O
japonica O
var O
. O
glaucocalyx O
along O
with O
two O
known O
compounds O
, O
namely O
arjunglucoside B
( O
2 O
) O
and O
kaempferol B
- I
3 I
- I
O I
- I
rutinoside I
( O
3 O
) O
. O

The O
series O
of O
analogues O
was O
used O
to O
examine O
the O
impact O
of O
the O
E O
- O
ring O
chloride O
in O
binding O
D B
- I
Ala I
- I
D I
- I
Ala I
and O
on O
antimicrobial O
activity O
. O

Tandutinib B
reversed O
ABCG2 O
- O
mediated O
drug O
resistance O
in O
ABCG2 O
- O
482 O
- O
R2 O
, O
ABCG2 O
- O
482 O
- O
G2 O
, O
ABCG2 O
- O
482 O
- O
T7 O
and O
S1 O
- O
M1 O
- O
80 O
cells O
and O
increased O
the O
accumulation O
of O
doxorubicin B
, O
rhodamine B
123 I
and O
[ B
H I
( I
3 I
) I
] I
mitoxantrone I
in O
ABCG2 O
- O
overexpressing O
cells O
. O

Two O
new O
daphnane O
- O
type O
diterpene O
esters O
, O
daphneresiniferins B
A I
( I
1 I
) I
and I
B I
( O
2 O
) O
, O
along O
with O
seven O
known O
diterpenes B
, O
yuanhuacine B
( O
3 O
) O
, O
yuanhuadine B
( O
4 O
) O
, O
yuanhuahine B
( O
5 O
) O
, O
genkwadaphnin B
( O
6 O
) O
, O
genkwanine B
A I
( O
7 O
) O
, O
genkwanine B
F I
( O
8 O
) O
, O
and O
genkwanine B
H I
( O
9 O
) O
, O
were O
isolated O
from O
the O
methanol B
extract O
of O
the O
flower O
buds O
of O
Daphne O
genkwa O

Oral O
administration O
of O
high O
- O
dose O
groups O
( O
12mg O
/ O
kg O
) O
CPF B
led O
to O
a O
significant O
increase O
in O
levels O
of O
reactive O
oxygen B
species O
, O
DNA O
- O
protein O
crosslinks O
, O
8 B
- I
hydroxy I
- I
2 I
- I
deoxyguanosine I
and O
malondialdehyde B
, O
decreases O
in O
acetylcholinesterase O
activity O
and O
glutathione B
level O
, O
as O
well O
as O
causing O
hepatic O
and O
renal O
histopathological O
change O
. O

Synthesis O
and O
Structure O
Activity O
Relationship O
of O
Tetrahydroisoquinoli B
- O
based O
Potentiators O
of O
GluN2C O
and O
GluN2D O
Containing O
N B
- I
Methyl I
- I
D I
- I
Aspartate I
Receptors O
. O

Aminoalkenes B
are O
unchanged O
in O
the O
presence O
of O
a O
zirconium B
monoamido I
complex O
{ B
PhB I
( I
C5H4 I
) I
( I
Ox I
( I
4S I
- I
iPr I
, I
Me2 I
) I
) I
2 I
} I
Zr I
( I
NMe2 I
) I
Cl I
or O
a O
cyclopentadienylmono B
( I
oxazolinyl I
) I
borato I
zirconium I
diamide I
{ B
Ph2B I
( I
C5H4 I
) I
( I
Ox I
( I
4S I
- I
iPr I
, I
Me2 I
) I
) I
} I
Zr I
( I
NMe2 I
) I
2 I
. O

We O
used O
atomic O
force O
microscopy O
( O
AFM O
) O
to O
study O
the O
dose O
- O
dependent O
change O
in O
conformational O
and O
mechanical O
properties O
of O
DNA O
treated O
with O
PT B
- I
ACRAMTU I
( B
[ I
PtCl I
( I
en I
) I
( I
ACRAMTU I
- I
S I
) I
] I
( I
NO3 I
) I
2 I
, O
( O
en O
= O
ethane B
- I
1 I
, I
2 I
- I
diamine I
, O
ACRAMTU B
= O
1 B
- I
[ I
2 I
- I
( I
acridin I
- I
9 I
- I
ylamino I
) I
ethyl I
] I
- I
1 I
, I
3 I
- I
dimethylthiourea I
. O

Antifouling O
alkyne B
- O
functionalized O
poly B
( I
N I
- I
hydroxyethyl I
acrylamide I
) I
( O
alkynyl B
- I
PHEAA I
) O
and O
antibacterial O
alkyne B
- O
functionalized O
poly B
( I
2 I
- I
( I
methacryloyloxy I
) I
ethyl I
trimethylammonium I
chloride I
) I
( O
alkynyl B
- I
PMETA I
) O
polymer O
brushes O
were O
clicked O
on O
the O
SS O
- O
azide B
surface O
. O

The O
cytoprotective O
effect O
of O
6b O
was O
also O
observed O
in O
6 B
- I
OHDA I
- O
treated O
neuronal O
PC12 O
cells O
, O
but O
not O
in O
SH O
- O
SY5Y O
or O
PC12 O
cells O
exposed O
to O
1 B
- I
methyl I
- I
4 I
- I
phenylpyridinium I
, O
indicating O
that O
the O
observed O
neuroprotection O
was O
dependent O
on O
the O
cytotoxic O
stimulus O
. O

A O
potential O
drawback O
with O
the O
use O
of O
mannitol B
as O
a O
bulking O
agent O
is O
its O
existence O
as O
mannitol B
hemihydrate I
( O
MHH B
; O
C6H14O6 B
( I
. I
) I
0 I
. I
5H2O I
) O
in O
the O
lyophile O
. O

Dialkyl B
5 I
- I
( I
hydroxymethyl I
) I
isophthalates I
are O
a O
novel O
group O
of O
synthetic O
C1 O
domain O
ligands O
that O
exhibit O
antiproliferative O
effect O
in O
HeLa O
cervical O
carcinoma O
cells O
. O

The O
antitumor O
pentacyclic O
triterpenoids O
, O
Lantadene B
A I
( I
1 I
) I
and I
B I
( O
2 O
) O
were O
isolated O
from O
the O
leaves O
of O
weed O
Lantana O
camara O
L O
. O

